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ABSTRACT OF THE DISSERTATION 
 
The Effect of Procedural Pain on Purines, MDA and Allantoin in 
Premature Infants 
 
by 
Megan Sue Holden 
Doctor of Philosophy, Graduate Program in Biochemistry 
Loma Linda University, June 2013 
Dr. Penelope Duerksen-Hughes, Chairperson 
 
Identifying and measuring the biochemical effects of procedural pain in infants is 
a continuing challenge for clinicians.  To address this issue we evaluated the relationship 
between procedural pain, ATP utilization (hypoxanthine and uric acid), and oxidative 
stress (MDA and allantoin) in premature infants.  Through these studies we found that 1) 
a single heel-lance significantly increases plasma uric acid in rabbit kits, 2) tape removal 
increases MDA and prevents a decrease in uric acid in the plasma of premature infants, 
and 3) a single dose of oral sucrose before a heel-lance is sufficient to significantly 
increase plasma markers of ATP utilization and oxidative stress.  These studies indicate 
that, in premature infants, ATP utilization and oxidative stress are altered by procedural 
pain and that oral sucrose, a common analgesia, may increase ATP breakdown.   
Next, we examined clinical factors that need to be considered when using the 
urinary concentrations of hypoxanthine, xanthine, uric acid, and allantoin to evaluate the 
biochemical effects of procedural pain.  Specifically, we determined the effects of 
gestational age, weight for gestational age, and neonatal morbidity on the urinary 
concentration of purines and allantoin.  We found infants born at earlier gestational ages 
had significantly higher urinary purine and allantoin concentrations compared to infants 
xvii 
born at later gestations, after 31 weeks.  Weight for gestational age also altered the 
urinary concentration of purines with small for gestational age infants having 
significantly lower urinary hypoxanthine compared to appropriate and large for 
gestational age infants.  In addition, respiratory morbidity significantly increased urinary 
purines, but not allantoin, within the late preterm population.  These data suggest that 
gestational age, weight for gestational age, and neonatal morbidity alter the urinary 
concentration of purine metabolites.  Allantoin was also found to be significantly altered 
by gestational age.  Based upon these data, we recommend conducting age-matched as 
well as weight for age-matched studies when using urinary purines and allantoin to 
evaluate the relationship between procedural pain and hypoxia on ATP utilization and 
oxidative stress.  Lastly, it is important to stratify subjects based on health status or 
morbidity, due to the significant effects of respiratory diseases on ATP use and oxidative 
stress.
1 
 
 
CHAPTER ONE 
INTRODUCTION 
 
Infants Feel Pain 
Before the 1980’s it was commonly believed that pain perception in neonates was 
blunted or absent.  Neonates were subjected to routine painful procedures and even 
surgery with no anesthesia or analgesia.  In 1987, however, Anand et al. reported that 
even premature infants have the anatomical structures and functional requirements 
necessary to perceive pain [1].  Further investigations on the development of pain 
pathways revealed that, due to immature decending pain inhibition pathways, neonates 
are likely to feel pain more intensely than adults and that this hypersensitivity is 
exacerbated in premature neonates [2, 3].   
In addition to feeling pain more intensely, infants who are exposed to repeated 
painful stimuli are more likely to exhibit sighs of hyperalgesia, a prolonged and 
exaggerated response to stimuli [3-6].  Research indicates that an insufficient release of 
inhibitory neurotransmitters contributes to hyperalgesia in premature infants [3].  Tissue 
injury can further promote hyperalgesia by stimulating an inflammatory response that, 
because of nerve ending proliferation in the developing newborn, results in 
hyperinnervation and increased pain perception [7-10].   
It has also been suggested that infants can learn to anticipate pain.  Goubet et al.  
demonstrated that premature infants who had their leg held up for 10 seconds prior to a 
heel stick showed significantly higher heart rate during leg lift on day five than on day 
2 
one [6].  Studies conducted by Taddio et al. reveled that full-term infants who were born 
to diabetic mothers and were therefore exposed to repeated heel lances in the first 24 to 
36 hours of life learned to anticipate pain [4].  This study also noted a heightened pain 
response during venipuncture for infants who were born to diabetic mothers and exposed 
to repeated heel lances.  Taken together, these studies, in addition to several others, 
clearly established that neonates perceive, feel, and may even remember or anticipate 
pain [11-13].  Despite the knowledge that infants feel pain, developing effective 
interventions and identifying the biochemical consequences pain in infants is a 
continuing challenge for clinicians. 
 
Painful Procedures In The NICU 
Infants admitted to the neonatal intensive care unit (NICU) are repeatedly 
subjected to noxious stimuli as part of their routine care.  In 2003 it was reported that 
infants in the NICU were exposed to roughly 14 ± 4 painful procedures per day and that 
pharmacologic, as well as non-pharmacologic, analgesia was rarely used before an 
invasive procedure [14].  This information was reaffirmed in 2008 when Carbajal et al. 
reported that NICU patients were exposed to an average of 12 ± 8 painful procedures per 
day and that many of these procedures were preformed without analgesia [15].  These 
procedures included, but were not limited to: suctioning, heel-lance, tape removal, IV line 
insertion/removal, intubation/extubation, lumbar puncture, and gastric tube insertion.  
While these procedures are necessary, the metabolic and physiological consequences of 
pain caused by these routine procedures in infants need to be examined further.  
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In addition to examining the metabolic and physiological consequences of pain, 
the efficacy of standard NICU pain management techniques needs to be examined.  One 
of the most common pain interventions for minimally invasive routine painful procedure 
in the NICU is oral sucrose.  Numerous studies report reductions in behavioral pain 
scores when oral sucrose in administered prior to heel lance [16, 17]; however, recent 
studies indicate that oral sucrose does not significantly reduce pain induced activity in 
neonatal brain or spinal cord nociceptive circuits suggesting that oral sucrose may not be 
effective at reducing pain [18].  The ability of oral sucrose to normalize the biochemical 
changes that result from procedural pain needs to be examined.    
 
Pain Response In Neonates 
It is well documented that exposure to painful procedures can result in acute 
metabolic and physiological changes like increased heart rate, tachycardia, decreased 
oxygen saturation, decreased transcutaneous PaO2 (partial pressure of oxygen in arterial 
blood), increased movement, altered somatosensory cortex hemodynamics, and increased 
cortisol [19-25].  In addition to the immediate alterations in physiological state observed 
to be associated with pain, research indicates that repeated painful procedures might have 
long-term consequences.  Brummelte et al. reported that greater neonatal procedural pain 
may contribute to impaired brain development in premature infants [26].  Studies have 
also reported higher pain response later in life in infants that were circumcised or exposed 
to repeated painful procedures [27-29].  While research supports the idea that pain during 
the neonatal period results in immediate and long term changes, little is known about the 
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effects of procedural pain on adenosine triphosphate utilization (ATP) and oxidative 
stress.  
 
A Theoretical Link Between Pain And Atp Depletion 
As described previously, common responses to painful procedures in neonates 
often involve increased heart rate and decreased oxygen availability.  Theoretically, this 
combination of events could result in a hypoxic-like state where ATP utilization 
surpasses ATP production and purine degradation products are formed.  Research 
indicates that increased heart rate can significantly increase ATP utilization [30].  
Because the main source of ATP is oxidative phosphorylation, increased cardiac ATP 
utilization is associated with increased myocardial oxygen consumption [31].  In order to 
accommodate for the increase in oxygen demand, cardiac output increases to ensure 
adequate oxygen delivery to the working tissues [32].  If oxygen consumption is not 
matched by oxygen delivery, cellular hypoxia can occur.  In premature infants, 
tachycardia has the potential to decrease cardiac output by degreasing stroke volume [32, 
33].  Specifically, tachycardia decreases stroke volume by limiting the time available for 
ventricular filling during diastole.  In addition, reductions in oxygen saturation are often 
seen in infants experiencing pain.  This combination of events has the potential to create a 
hypoxic-like state where ATP production cannot match ATP utilization.  This would be 
reflected in plasma and urine by increased purine production.   
 In addition to variations in heart rate, hypoxemia also has the potential to reduce 
ATP production.  In patients with sleep apnea, plasma uric acid levels positively correlate 
with the number of obstructive respiratory episodes and oxygen desaturations during 
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sleep [34].  Furthermore, hypoxemia was shown to significantly decrease ATP and 
increase inosine monophosphate in isolated rat hearts without significantly altering 
phosphocreatine [35].  This study shows a relationship between hypoxemia and ATP 
breakdown; however, plasma levels of ATP breakdown products were not evaluated.  In 
infants, it was shown that a significant inverse relationship exists between PaO2 and uric 
acid (serum and urine) [36].  Taken together, these studies indicate that reductions on 
oxygen saturation have the potential to alter the production of purine nucleotides; 
however, the effects of transient decreases in oxygen saturation on purine production are 
unknown.     
 
The Purpose Of These Studies 
  Based upon the physiological responses observed to be associated with procedural 
pain, we hypothesized that markers of hypoxia, a condition associated with ATP 
depletion, could be used to evaluate the biochemical effects of procedural pain on ATP 
utilization and oxidative stress in premature infants.  We began our studies by reviewing 
literature on well-established markers of hypoxia in order to determine which ones would 
be best for evaluating ATP utilization and oxidative stress in small volumes of plasma 
and urine (Chapter 2).  Next we determined the most efficient means of quantifying the 
chosen markers (Chapter 3).  Then we determined the effect of acute pain on hypoxia 
associated plasma markers of ATP catabolism (purines) and oxidative stress (MDA, 
allantoin) in premature infants.  To accomplish this we first developed an animal model 
to measure the effect of a single heel-lance on plasma uric acid concentrations (Chapter 
4).  An animal model was chosen to control for the NICU environment and to enable the 
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researchers to measure the direct effect of a heel lance on plasma uric acid.  Then we 
measured the changes in plasma uric acid and MDA in premature infants exposed to a 
common painful NICU procedure, tape removal (Chapter 5).  Finally, we used our 
markers to evaluate the efficacy of a commonly used intervention, oral sucrose (Sweet-
Ease), on relieving pain caused by a single heel lance (Chapter 6).  These studies 
revealed that 1) biochemical markers of hypoxia can be used to evaluate the effects of 
acute pain on ATP catabolism and oxidative stress, 2) even acute pain can cause 
significant changes in these markers, and 3) markers of ATP catabolism and oxidative 
stress may be useful in evaluating the efficacy of analgesia.   
In the next set of studies we evaluated the clinical factors that may affect the 
utility of these compounds as urinary markers of pain (Chapter 7).  Specifically, we 
determined the effect of gestational age, weight for gestational age, and common neonatal 
morbidities on the urinary concentrations of purines and allantoin in premature infants. 
Late preterm infants were chosen to evaluate the effects of morbidity for several reasons.  
First, this population is less likely to have central catheter lines when compared to more 
premature infants.  Second, research has already established the effects of morbidity on 
purine concentrations in infants with younger gestational ages; however, the effect of 
both mild and severe forms of morbidity on the urinary concentrations of purines and 
allantoin on late preterm infants is unknown.  Third, the late preterm population is 
understudied and often clinically managed as if they were term.  Lastly, we hypothesized 
that the urinary excretion of purine and allantoin would be inversely related to gestation 
and wanted to control for this in our morbidity studies.  These studies revealed that 
gestational age, weight for gestational age, and neonatal morbidity alter the urinary 
7 
excretion of purine and allantoin and need to be accounted for when using these 
compounds to evaluate the metabolic consequences of pain in premature infants.   
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Abstract 
Neonatal hypoxia is a clinical condition with detrimental biochemical and clinical 
outcomes including production of reactive oxygen and nitrogen species, ATP depletion, 
developmental abnormalities and growth retardation.  Diagnostic approaches for hypoxia 
are largely based on nonspecific clinical criteria such as Apgar score, umbilical cord pH, 
and fetal heart rate monitoring.  Since our understanding of the biochemical processes of 
hypoxia has improved, several biochemical markers have been developed.  This review 
highlights the use of hypoxanthine, xanthine, uric acid, xanthine oxidase, 
malondialdehyde (MDA), nitrotyrosine and lactate as markers of hypoxia in animal 
models, preterm neonates, and full-term neonates.   
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Background 
Hypoxemia refers to low oxygen concentration in the arterial blood, while 
hypoxia suggests inadequate oxygen availability to the tissues.  Hypoxia frequently 
occurs in the neonatal intensive care unit (NICU) and is a consequence of neonatal 
diseases, such respiratory distress syndrome, persistent pulmonary hypertension of the 
newborn, apnea of prematurity, bronchopulmonary dysplasia, hemorrhagic diseases and 
congenital heart disease.  Respiratory distress that result in hypoxia occur in 10% of term 
newborn [1].  This incidence increases as gestational age decreases [2].  Upon admission 
to the NICU, infants are handled up to 110 times/day [3].  Of these handling episodes, 
75% result in oxygen desaturation [4].  Owing to the lack of reliable methods to quantify 
hypoxia at the bedside, it is not known if these hypoxemic events result in cellular 
hypoxia.  Hypoxia may be the result of:  
 Low PO2 of the inspired air or poorly oxygenated lungs 
 Decreased hemoglobin 
 Deficiencies in oxygen transport and/or utilization 
 
Alveolar hypoxia represents the condition of reduced alveolar PO2, often owing to 
some restriction in gas exchange.  This can elicit a compensatory vasoconstriction of the 
arterial vessels leading to the affected alveoli, thus minimizing the perfusion of under-
oxygenated alveoli.  Hypoxemic hypoxia is the form of hypoxia that is caused by 
hypoxemia despite adequate tissue perfusion.  Sometimes also referred to as hypoxic 
hypoxia, this condition arises as a result of a reduction in the delivery of oxygen to the 
pulmonary capillary system, ultimately leading to low intracellular oxygen 
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concentrations.  This represents the most common form of hypoxic insult in neonates and 
tends to exacerbate numerous diseases, abnormalities and developmental problems [5-8].  
Furthermore, neonatal hypoxia is associated with a high morbidity and mortality rate.  In 
order to identify a condition that can have its effects anywhere in the body, it is important 
that the condition be categorized according to its biochemical effects on the body.   
The detrimental biochemical consequences of hypoxia are due to the processes that occur 
during anaerobic metabolism (Figure 1).  In times of oxidative stress, metabolism is 
forced to switch from aerobic to anaerobic and steady-state concentrations of ATP will 
decrease [9].  The decrease in ATP is due to a lack of oxidative phosphorylation coupled 
with continued utilization of ATP for energy.  One of the many functions of oxidative 
phosphorylation is to generate a proton gradient to drive the enzyme, ATP synthase, to 
synthesize ATP from ADP and inorganic phosphate [10, 11].  Since oxygen is required 
for oxidative phosphorylation to generate the proton gradient that drives ATP synthase, 
insufficient amounts of oxygen results in reduced or halted ATP production.  The 
combination of inhibited ATP production and lack of oxygen puts the body in an energy-
deprived state.  To compensate for this, molecules containing high-energy phosphate 
bonds, such as ATP, are broken down in order to provide energy for normal cellular 
processes [9].  Furthermore, the body will switch to anaerobic metabolism, converting 
pyruvate to lactate in order to re-generate NAD+, enabling glycolysis to continue 
producing ATP (Figure 2).  However, the resulting ATP is rapidly consumed.  Thus, 
even with continued ATP production via anaerobic glycolysis, there is a steady decrease 
in cellular energy levels accompanied by increased release of free adenosine.  The free  
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Figure 1:  Formation of the Biochemical markers of hypoxia. NMDA: N-methyl-D-aspartate; 
MDA: Malondialdehyde; NOS: Nitric Oxide Synthase; Pi: Inorganic Phosphate; ROS: Reactive 
Oxygen Species.  
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Figure 2:  Cori Cycle.  During anaerobic metabolism, pyruvate is converted into lactate to 
regenerate NAD+ in order to enable glycolysis to continue. 
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adenosine will be degraded to inosine, hypoxanthine, xanthine, and finally to uric acid.  
The latter two steps are catalyzed by xanthine oxidoreductase, a molybdopyranopterin-
containing enzyme, that may be present in two distinct functional forms, xanthine 
dehydrogenase or xanthine oxidase [12, 13].  Under normoxic conditions, the enzyme 
form responsible for the degradation of hypoxanthine to xanthine and xanthine to uric 
acid is xanthine dehydrogenase [14].  Xanthine dehydrogenase is dependent on NAD+, 
one of the major byproducts of oxidative phosphorylation [15].  Anaerobic glycolysis 
during hypoxia leads to increased consumption of NAD+, while reduced oxidative 
phosphorylation effectively decreases NAD+ production.  Together these processes result 
in reduced levels of NAD+.  Under these hypoxic conditions, xanthine dehydrogenase is 
converted into xanthine oxidase [16].  Xanthine oxidase is activated during reperfusion 
and performs the same purine degradation steps as xanthine dehydrogenase, with the 
exception that xanthine oxidase uses oxygen instead of NAD+ as an oxidant [16].  A side 
effect of this reliance on oxygen is the production of reactive oxygen species (ROS), such 
as superoxide and hydrogen peroxide, as well as reactive nitrogen species (RNS), such as 
peroxynitrite.  In addition to the conversion of xanthine dehydrogenase into xanthine 
oxidase, reduced levels of NAD+ also lead to the inhibition of the citric acid cycle, 
shifting pyruvate conversion to lactate, accompanied by a temporary compensatory 
NAD+ return [17].   
 In the brain, hypoxia-induced membrane depolarization triggers an increase in 
intracellular calcium, facilitated by a glutamate-induced increase in NMDA receptors 
[18-20].  High intracellular calcium levels also contribute to the conversion of xanthine 
dehydrogenase to xanthine oxidase, and the subsequent production of ROS and RNS [9, 
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21].  These proposed mechanisms are reinforced by data that demonstrate that the 
metabolic changes induced by hypoxia result in an increase in the concentration of ROS 
[22-24].  The major producer of ROS during hypoxia is xanthine oxidase, but it has been 
proposed that the mitochondria, nicotinamide adenine dinucleotide phosphate oxidase 
and free fatty acids may also contribute to the generation of ROS [21, 25-27].  Owing to 
the numerous biochemical changes that occur as a result of the hypoxia-induced 
transition from aerobic to anaerobic metabolism, there are a growing number of potential 
biochemical markers that may be useful for quantitative clinical evaluation of the severity 
of sustained hypoxic stress or trauma.  This review will not discuss hypoxia markers 
detected by medical imaging or UV-Vis spectroscopy. 
 
Clinical Markers Of Hypoxia 
The currently accepted method of diagnosing fetal/perinatal hypoxia involves a 
combination of nonspecific indicators: Apgar score, umbilical cord pH, Sarnat staging, 
and fetal heart rate monitoring.  The Apgar score evaluates five elements, each on a scale 
of 0-2, at 1 and 5 minutes after birth.  These five elements are heart rate, respiratory 
effort, muscle tone, reflex irritability, and color [28].  However, it has been demonstrated 
that several obstetric risk factors other than hypoxia are associated with a low 5-min 
Apgar score in term infants and that the Apgar score has low interobserver reliability [28-
30].  Therefore, while this method may provide a general diagnosis of physiologic stress, 
it does not correlate well with the severity of the hypoxic insult.  Furthermore, several 
authors have shown the limited utility of the Apgar score in preterm infants [31, 32].   
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Fetal heart rate monitoring is utilized widely for the assessment of fetal wellbeing, 
but it can result in false-positive diagnosis of fetal asphyxia [33].  Another tool utilized 
clinically is Sarnat staging, a method for defining the stages of encephalopathy in 
asphyxiated neonates, without electroencephalography.  This method demonstrates a 
good correlation between stages of encephalopathy and outcome, but without adequate 
predictive value for survival [34-36].  Furthermore, the inability to define clear stages of 
encephalopathy in preterm infants greatly reduces the usefulness of Sarnat staging for this 
vulnerable age group [37].  For all of these reasons, a combination of methods is used to 
diagnose hypoxia.  Even with a combination of diagnostic methods, the level of hypoxia 
experienced by a neonate can be difficult to evaluate because it ranges from minor to 
severe and its effects can present in the form of a wide array of symptoms.   
Several factors, from the mother as well as the fetus, can contribute to the risks of 
perinatal hypoxic stress.  Chronic hypertension, infection, chronic substance abuse, pre-
existing diabetes mellitus, intrauterine growth restriction and pre-eclampsia are some of 
the maternal factors that have been linked to neonatal hypoxia [38-41].  Other factors 
include prolapsed umbilical cord, prolonged labor, nuchal cord, and placental abruption 
[42-44].  With such a vast range of possible etiologies, it is not surprising that studies 
have shown this condition to be the third leading cause of infant mortality in low risk 
women in the United States [45].  Among surviving neonates, severity of hypoxia is 
thought to correlate with neurological development and overall growth.  Hypoxia has 
been linked to developmental malformations in the brain, heart, stomach, liver, and other 
organs [46-48].  Despite the fact that hypoxia is a major contributor to neonatal mortality 
by direct or indirect means, diagnostic methods remain generally qualitative and 
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nonspecific [49].  In order to successfully identify and measure the severity of neonatal 
hypoxia, reliable quantifiable biochemical markers need to be evaluated for 
implementation in the clinical setting.   
 
Biochemical Markers 
There are several biochemical markers of hypoxia that are currently being 
evaluated to aid in the clinical diagnosis of hypoxia.  The ultimate goal of these 
biochemical markers is not only to quantify hypoxia, but also to predict the severity of 
hypoxic insult.  This would allow immediate identification and treatment of high-risk 
neonates.  Some of the most promising candidate markers for quantification of the 
severity of hypoxia and prediction of its sequelae are purine degradation products, ROS 
and lactate levels. 
 
Detecting Hypoxia Using Purine Biochemical Markers 
Purine metabolites were linked to hypoxia as early as 1963 when Berne observed 
elevated levels of inosine and hypoxanthine in the myocardium of cats and dogs exposed 
to hypoxia [50].  Since then, a number of studies evaluated the usefulness of purine 
metabolites from urine, serum, cerebrospinal fluid (CSF) or other tissues in animal 
models as well as humans.  Several studies demonstrated the reliability of purines as 
biochemical markers for the detection of hypoxia in neonates, children and adults [51-
55].  Furthermore, the enzyme responsible for the final two degradation steps of purine 
metabolism, xanthine oxidase, is also being evaluated as a potential biochemical marker 
for hypoxia.  Since xanthine oxidase is the predominant form of xanthine oxidoreductase 
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under conditions of hypoxia-reperfusion, as opposed to xanthine dehydrogenase which is 
present under normoxic conditions, it has the potential to be a useful biochemical marker 
of hypoxia. 
 
Purine Metabolites In Animal Models 
Several studies of hypoxia in mammals including sheep, rats, pigs, and rabbits 
have demonstrated elevated levels hypoxanthine, xanthine, and uric acid in response to 
oxidative stress (Table 1).  It was shown in the fetal sheep that, during times of severe 
hypoxia, the concentration of hypoxanthine in the CSF increases [56].  This same study 
also demonstrated that serum hypoxanthine and xanthine in the fetal sheep increased in 
response to mild and severe hypoxia [56].  In the adult rat, increased serum levels of uric 
acid were reported as early as 24 h after a hypoxic insult [57].  In the pig and piglet 
models, hypoxia-induced rises in purine degradation products were observed in serum, 
urine, and CSF samples [58].  Further work with pigs and piglets also demonstrated 
increased hypoxanthine, xanthine, and uric acid in response to hypoxia in the vitreous 
humor [59].  These animal models demonstrate that purine metabolites may serve as 
useful biochemical markers of hypoxia in a number of mammals, and further efforts to 
study the relationship between the severity of hypoxia and these biochemical markers are 
needed.  Physiological relevance could be strengthened by examination of correlation of 
purine metabolites with brain white matter injury in the various animal models.  Previous 
studies demonstrated that many neurodevelopmental aspects of nonhuman mammals 
parallel human brain development, and that the brain development of some animal 
 
 
22 
Table 1: Biochemical markers of Hypoxia in Animals. CSF: cerebrospinal fluid; 1H-NMR: 
proton nuclear magnetic resonance; MDA: Malondialdehyde 
 
Biochemical 
marker 
Species Method Of 
Measurement 
Condition Of 
Animal 
Source Of 
Sample 
Recorded 
Level 
Ref. 
Hypoxanthine Fetal 
Sheep 
1H-NMR [65] 
 
Severe 
Hypoxia 
 
CSF 53 μmol/L [56] 
Arterial 
Blood 
58.1±25.6 
μmol/L 
Normoxic Arterial 
Blood 
14.3±11.3 
μmol/L 
Pig HPLC[66, 67] Hypoxemic 
 
CSF 39.9 μmol/L [58] 
Serum 103.6 μmol/L 
Urine 87.1 μmol/L 
Normoxic CSF 18.1 μmol/L 
Serum 25.4 μmol/L 
Urine 21.3 μmol/L 
Xanthine Fetal 
Sheep 
1H-NMR [65] Severe 
Hypoxia 
Arterial 
Blood 
12.1±6.5 
μmol/L 
[56] 
Normoxic Arterial 
Blood 
4.1±0.8 
μmol/L 
Pig HPLC[66, 67] Hypoxemic CSF 10.6 μmol/L [58] 
Serum 48.1 μmol/L 
Urine 12.6 μmol/L 
Normoxic CSF 4.0 μmol/L 
Serum 0.7 μmol/L 
Urine 4.0 μmol/L 
Uric Acid 
 
 
 
 
Rat Modified 
Phosphotungst-
ate Method[68] 
Hypoxic Serum 3.21±1.0 
mg/dL 
[57] 
Normoxic Serum 0.98±1.0 
mg/dL 
Pig HPLC[66, 67] Hypoxemic CSF 16.3 μmol/L [58] 
Serum 208 μmol/L 
Normoxic CSF 3.1 μmol/L 
Serum 15.3 μmol/L 
Xanthine 
Oxidase 
Piglet Radioactivity 
Of Uric Acid 
From The 
Conversion of 
C14-Xanthine 
Hypoxic Plasma 4-18 μU/ml [69] 
Normoxic Plasma Undetectable 
MDA 
 
 
 
Rat Pup 
 
 
Methods 
Developed By  
Ohkawa et a1 
[70] 
& Lowry et al 
[71] 
Hypoxic 
 
Intestinal 
Tissue 
3.826±0.425 
nmol/mg 
protein 
[72] 
Normoxic Intestinal 
Tissue 
2.164±0.229 
nmol/mg 
protein 
Nitrotyrosine Rat Optical Density 
Of Western 
Blot Bands 
Hypoxic Striatum 
Supernatant  
133.5±16.8% [73] 
Normoxic Striatum 
Supernatant 
104.3±10.0% 
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models at full- term coincide with brain development of preterm human neonates [60].   
This supports the use of animal models to evaluate the extent of brain damage as a result 
hypoxic insult. 
Several animal models were employed to examine the relationship between 
hypoxia and the expression of xanthine oxidase activity.  These include piglets, rats, and 
Chinese hamsters.  In 1995, increased circulation levels of xanthine oxidase were 
reported, from non- measurable to detectable, in five of 19 piglets, after experimental 
ischemia followed by reoxygenation (Table 1) [61].  However, this study also indicated 
that the xanthine oxidase levels did not correlate with documented brain damage [61].  In 
a rat liver and cultured liver cells, xanthine oxidase activity was shown to have a positive 
correlation with duration and severity of hypoxia [62, 63].  Increased xanthine oxidase 
activity was also observed in Chinese hamster V79 cells, which were exposed to hypoxia 
followed by reoxygenation [64].  These animal models demonstrate that purine 
biochemical markers of hypoxia are not limited to one species, and efforts to correlate the 
brain injury with the biochemical markers of hypoxia found in serum, urine, and CSF 
should be further evaluated.  
 
Purine Metabolites In Hypoxic Full-Term Neonates 
Increased purine degradation products were demonstrated in full-term neonates that 
experienced periods of hypoxia (Table 2).  In 1982 Harkness et al. reported a 
noninvasive way to measure hypoxanthine and xanthine in the urine of full-term neonates 
[53].  It was demonstrated that hypoxanthine and xanthine levels were higher in neonates 
following an apneic attack and that the severity of neurological damage correlated with 
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excreted hypoxanthine and xanthine [53].  Increased hypoxanthine and xanthine were 
also documented in serum of asphyxiated full-term infants [74].  In addition, full-term 
neonates were reported to have elevated hypoxanthine, xanthine and uric acid in CSF as a 
result of hypoxia [54].  In this latter report, hypoxanthine was the better indicator of brain 
damage [54].  Additional studies have also demonstrated elevated levels of serum 
hypoxanthine in 48% of full-term, hypoxic neonates [75].  There are few data to 
substantiate xanthine as a helpful biochemical marker of hypoxia in full-term neonates, 
but this may be due to relatively low concentration of xanthine compared to 
hypoxanthine or uric acid [76].  Elevated urine or serum uric acid concentrations were 
observed in hypoxic full-term neonates on day one of life and, to a lesser extent, on day 3 
of life [77].  Uric acid:creatinine ratio was proposed as a reliable biochemical marker for 
the diagnosis of perinatal asphyxia and for the determination of the stage of hypoxic 
ischemic encephalopathy [78].  Despite the correlation between increased uric acid and 
hypoxia, some studies indicated that uric acid may not be as useful in predicting the 
severity of the resultant brain injury, based on observations that mean uric acid levels do 
not significantly differ between infants with and without severe brain injury or between 
those with severe, moderate or mild hypoxic ischemic encephalopathy [89, 90].  
Nevertheless, hypoxanthine or xanthine measurements in serum or plasma show promise 
in predicting the amount of injury caused by hypoxic insult. 
The role of xanthine oxidase in the hypoxic full-term neonate is unclear because 
well-conducted studies that report measurements of this enzyme are still lacking.  
However, there are some reports of functional xanthine oxidase measurements in adults 
and in neonates with sepsis, clearly under stressful conditions (Table 2).  Increased 
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Table 2. Biochemical markers of Hypoxia in Full Term Neonates. CSF: cerebrospinal fluid; 
GCMS: Gas Chromatography Mass Spectrometry  
Biochemical Marker Method Of 
Measurement 
Condition Of 
Patient 
Source Of 
Sample 
Recorded 
Level  
Ref. 
      
Hypoxanthine HPLC[79] Hypoxic CSF 25.3 μmol/L [80] 
Normoxic CSF 1.8-5.5 μmol/L 
Xanthine HPLC[79] Hypoxic CSF  35.8 μmol/L [80] 
Normoxic CSF 0.9-9.1 μmol/L 
Uric Acid HPLC[79] Hypoxic CSF 70 μmol/L [80] 
Normoxic CSF 30±25 μmol/L 
Auto-analyzer 
Hitachi 747 
Uricase 
Enzymatic 
Kinetic 
Method 
Mild 
 Hypoxia 
Urine 0.95±0.55 
 Uric Acid/Cr 
[81] 
Moderate  
Hypoxia  
Urine 2.16±0.34 
Uric Acid/Cr 
Severe  
 Hypoxia 
Urine 3.33±0.73 
Uric Acid/Cr 
Xanthine Oxidase Horecker & 
Heppel’s 
Method[82] 
Septic Serum 5.27 (2.07) 
μmol/min/ml 
[83] 
Control Serum 3.43 (1.27) 
μmol/min/ml 
MDA Seethambaram 
& Das’ s 
Method[84] 
Septic Serum 9.5 (1.6)  
μmol/hr/dl 
[83] 
Control Serum 7.0 (0.78) 
μmol/hr/dl 
Thiobarbituric 
Acid 
Reaction[85] 
Delivery 
Room 
Resuscitation 
Serum 6.96±8 1.12 
μmol/L 
[86] 
Urine 4.67±8 1.50 
μmol/L 
Control Serum 5.26±8 0.63 
μmol/L 
Urine 2.45±8 0.56 
μmol/L 
Nitrotyrosine Immunohistoc
hemical 
Staining 
Asphyxiated Thalamus 70% [87] 
Olives 68% 
Cerebellu
m  
33% 
Pons 29% 
Nitrotyrosine metabolites GCMS Normoxic Urine  
 
[88] 
3-nitro-4-hydroxyphenyl- 
acetic acid (NHPA)  
   31.47± 7.27 
ng/ml 
para-hydroxyphenyl-acetic 
acid (PHPA) 
    
2.12±0.79 
mg/ml 
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xanthine oxidase activity was reported in neonates with sepsis, but this study sampled 
patients irrespective of gestational age and specifically excluded asphyxiated infants [91].  
Elevated plasma xanthine oxidase activity was also reported in adults with acute 
respiratory distress syndrome [92].  Higher levels of xanthine oxidase in both maternal 
and fetal plasma were reported in pregnancies complicated by pre-eclampsia [93].  Much 
more work is needed before xanthine oxidase can considered as a potential biochemical 
marker of hypoxia in full-term neonates. 
 
Purine Metabolites In Preterm Neonates 
Purine metabolites, measured in urine or serum, were proposed to be helpful 
biomarkers of hypoxia in preterm neonates.  Urinary uric acid and xanthine, but not 
hypoxanthine, were reported to be significantly elevated in the hypoxic neonates on day 1 
and 2 of life when compared to normoxic neonates [76].  More recently, however, it was 
demonstrated that serum hypoxanthine levels were increased in hypoxic preterm infants 
at birth and continued to be elevated until 7 day of life (Table 3)[94].  Buonocore et al. 
further substantiated the reliability of purine degradation products as biochemical 
markers of hypoxia in preterm neonates, reporting increased serum levels of 
hypoxanthine, xanthine and uric acid (Table 3) [102].  Subsequently, a correlation was 
documented between serum levels of xanthine or hypoxanthine and periventricular-
intraventricular hemorrhage, a condition that affects 15-20% of preterm infants[103]. A 
group of investigators also suggested the use of xanthine oxidase as a biochemical marker 
of hypoxia in the preterm neonates.  A study involving normoxic and hypoxic preterm 
infants demonstrated that the xanthine oxidase activity in arterial blood was elevated 4 h 
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Table 3. Values of biochemical markers of hypoxia in preterm neonates. ABST: 2,2’-azino-
bis(3-ethylbenzthioazoline-6-sulphonic acid); GCMS: Gas Chromatography Mass Spectrometry. 
after birth in the hypoxic poor outcome group when compared with control groups [104].  
Biochemical 
Marker 
Method Of 
Measurement 
Condition Of 
Patient 
Source Of 
Sample 
Recorded 
Level 
Ref. 
      
Hypoxanthine HPLC Hypoxic Cord Blood 3.9 ± 2.5 
μg/ml 
[95] 
Normoxic Cord Blood 1.6 ± 1.4 
μg/ml 
HPLC Hypoxic Plasma 3.89± 0.46 
μg/ml 
[96] 
Normoxic Plasma 1.13± 0.16 
μg/ml 
Xanthine HPLC Hypoxic Plasma 1.16± 0.2 
μg/ml 
[96] 
Normoxic Plasma 0.56± 1.71 
μg/ml 
Uric Acid HPLC Hypoxic Plasma 51.77± 4.01 
μg/ml 
[96] 
Normoxic Plasma 21.69± 3.3 
μg/ml 
Xanthine Oxidase Spectrophoto-
metric Monitoring 
& Conversion of 
Hypoxanthine To 
Urate & 
Oxidation Of The 
Chromogren 
ABTS 
Hypoxic 
 
Plasma 
 
4.7±0.6 
mU/ml 
[97] 
Normoxic Plasma 
 
1.1±0.2 
mU/ml 
MDA HPLC[98] Hypoxic Plasma 0.52±0.20 
nmol/ml 
[83, 
99] 
Seethambaram & 
Das’ s 
Method[84] 
Hypoxic Plasma 9.19 (1.28) 
μmol/hr/dl 
Nitrotyrosine Solid-phase,  
Antibody-Capture 
Immunoradio-
chemical 
Assay[100] 
Developed 
Bronchopulmonary 
Dysplasia 
Plasma 0.05-1.3 
ng/mg protein 
[101] 
Did Not Develop 
Bronchopulmonary 
Dysplasia 
Plasma Non 
Detectable– 
0.25 ng/mg 
protein 
Nitrotyrosine 
Metabolites 
GCMS Normoxic Urine  [88] 
3-nitro-4-
hydroxyphenyl- 
acetic acid (NHPA) 
   14.58± 4.49 
ng/ml 
 
para-
hydroxyphenyl-
acetic acid (PHPA) 
   0.99±0.38 
mg/ml 
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As was the case with full-term infants, there is little data on the levels of xanthine oxidase 
in the preterm neonates, but the information gained thus far suggests that xanthine 
oxidase may be an important marker of hypoxia.  
 
Detecting Hypoxia Using ROS & RNS Biochemical Markers 
Products of short-lived ROS or RNS, specifically malondialdehyde (MDA) and 
nitrotyrosine (Figure 1) may also serve as biochemical markers of hypoxic stress.  MDA 
is a thiobarbituric acid–reacting substance that is formed by the action of ROS on lipid 
membranes [49, 105, 106].  Because hypoxia and reoxygenation was shown to generate 
ROS, and MDA measurement is a commonly used indicator of oxygen induced radical 
damage [105, 107], it was proposed that MDA could be used as a biochemical marker of 
hypoxia reoxygenation and may even correlate with the severity of cellular or tissue 
damage and outcome.  Other lipid peroxidase products, such as lipid hydroperoxides, 
have been shown to increase in response to acute cerebral ischemia complicated by 
hypoxia and reperfusion, but MDA was shown to increase by a greater percentage than 
lipid hydroperoxides [108].  Nitrotyrosine is generally formed by the reaction of 
peroxynitrite with free or bound tyrosine residues, but can also be formed as a byproduct 
of myeloperoxidase released from neutrophils during an inflammatory response [109].  
Nitric oxide can react with a suitable ROS, such as superoxide anions (O2∙
−), to form 
peroxynitrite [110, 111].  However, nitric oxide formation is dependent on nitric oxide 
synthase, an enzyme that is induced during the inflammatory response [109] and 
activated by elevated intracellular calcium levels [21].  In adults, investigators showed 
that CSF nitrotyrosine levels can be used as a reliable predictor of poor neurological 
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outcomes, making nitrotyrosine of key interest in correlating severity of hypoxia damage 
with outcome [112]. 
 
ROS & RNS In Animal Models 
Several animal studies using mouse, rat or goat models, demonstrated the 
reliability of MDA as a marker of hypoxia and reoxygenation.  Representative reported 
values of MDA levels are presented in Table 1.  In the adult mouse model, it was shown 
that severe, chronic intermittent hypoxia results in a 60% increase in liver MDA while 
moderate, chronic intermittent hypoxia results in a 25% increase in liver MDA levels 
[113].  These data indicate that MDA may be helpful in determining the severity of 
hypoxia.  A study on necrotizing enterocolitis showed that rat pups exposed to hypoxia 
and reoxygenation exhibited significantly elevated intestinal tissue MDA in comparison 
to rat pups exposed to normoxic conditions [6].  MDA levels in other tissues as well as 
body fluids were also studied.  Elevated serum levels were observed in rats exposed to 
hypoxia and reoxygenation [114].  Similarly, elevated plasma levels of MDA were 
observed in fetal goats subjected to cord occlusion [115].   
Although several studies demonstrate the usefulness of MDA as an indicator of 
hypoxia, there are some factors that need to be taken into consideration when utilizing 
MDA as a biochemical marker of hypoxia and reoxygenation.  A study by Yamada et al. 
reported that fetal plasma MDA levels were significantly elevated after the initiation of 
maternal oxygen supplementation [115].  Furthermore, Loiseaux-Meunier et al. 
demonstrated elevated levels of MDA in adults that received hyperoxia oxygen therapy 
[116].  This suggest that oxygen supplementation in the absence of hypoxia can also 
increase plasma MDA levels. 
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The effects of hypoxia on nitrotyrosine levels were also studied in several animal 
models including rabbit and rat (Table 1).  Western blot, immunohistochemical, and 
HPLC techniques were commonly employed to demonstrate elevated production of 
nitrotyrosine after hypoxic exposure.  A group of investigators, employing HPLC with 
electrochemical detection, found increased nitrotyrosine formation from protein bound 
tyrosine in brain tissue of fetal rabbits following repetitive uterine ischemia-reperfusion 
[117].  Nitrotyrosine quantitation was further substantiated by the observation that 
nitrotyrosine levels were reduced following the administration of a selective neuronal 
nitric oxide synthase inhibitor to fetus [117].  Similarly, nitrotyrosine formation was 
evaluated immunohistochemically and by Western blotting in striatal samples from rats 
exposed to hypobaric hypoxia.  Increased nitrotyrosine levels accompanied increased 
levels of neuronal, constitutive and endothelial nitric oxide synthase in rat caudate 
putamen [118].  Since nitrotyrosine is elevated under conditions of oxidative stress and 
since it is also a known mediator of myeloperoxidase, an enzyme present under 
inflammatory conditions [108], it may be helpful to use nitrotyrosine as a marker of 
hypoxia induced inflammation cell damage.  Elevated nitrotyrosine was colocalized in 
the brains of hypoxic rats with several indicators of cellular injury, including a loss of 
microtubule-associated protein-2, presence of active caspase-3, nuclear translocation of 
apoptosis-inducing factor and evidence of specific DNA strand breaks [119].  
Colocalization of nitrotyrosine with markers of cell damage strengthens its potential 
utilization as a clinical indicator of brain damage that occurs after hypoxia. 
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ROS & RNS Markers In Full-Term Neonates 
Biochemical markers of ROS and RNS were employed in several studies as 
indicators of hypoxia in neonates (Table 2).  Kumar et al. compared serum and urinary 
concentrations of MDA between full-term neonates that received delivery-room 
resuscitation and a healthy group of control neonates [120].  They observed elevated 
levels of serum and urinary MDA in delivery room resuscitated neonates, and noted that 
infants with clear signs of fetal and neonatal distress (meconium staining, hypoxic 
ischemic encephalopathy or death), exhibited the highest levels of MDA [120].  Similar 
increases in MDA levels, as a result of hypoxia, were also demonstrated in the plasma of 
blood samples taken from placental part of the umbilical cord [121].  While some data 
regarding urinary and serum levels of MDA are available for hypoxic and normoxic 
neonates, little is known regarding the MDA levels in the CSF.  More studies using MDA 
measurements are required to definitively characterize lipid peroxidation due to oxidative 
stress in neonates.  Furthermore, there is evidence that factors other than hypoxia can 
affect the levels of MDA.  Kahw et al. recorded significantly elevated levels of plasma 
MDA in umbilical cord and maternal blood samples after the administration of maternal 
oxygen supplementation [122].  It has also been observed that small-for-gestational-age 
term infants, born to undernourished mothers, had higher serum MDA levels than 
average for gestational age infants born to healthy mothers[123].  More studies are 
required to characterize factors that alter MDA in biologic fluids and as a potential 
marker of cellular damage induced by oxidative stress. 
Elevated nitrotyrosine was documented in human neonatal brain (Table 2).  A 
study of 22 full-term asphyxiated neonates demonstrated increased nitrotyrosine staining 
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in brain tissue samples [124].  Nitrotyrosine was also found in the spinal cord of 
asphyxiated full-term neonates.  A study of 18 asphyxiated neonates demonstrated 
positive nitrotyrosine staining in five, with the highest nitrotyrosine staining in an infant 
who died shortly after the hypoxic-ischemic insult [125].  Further work is needed to 
obtain information regarding nitrotyrosine levels in CSF, serum, and urine of full-term 
infants with or without hypoxia. 
 
ROS & RNS Markers In Preterm Neonates 
Malondialdehyde levels were measured in preterm neonates in several reports.  
Serum MDA levels were found to be markedly higher in hypoxic preterm neonates in 
umbilical cord blood as well as blood samples on day 4 of life when compared to hypoxic 
term neonates [99].  Elevated urinary MDA was reported in infants with 
bronchopulmonary dysplasia [126].  It has also been observed  that the MDA was 
inversely related to birthweight [126].  Urinary MDA measurements gained legitimacy 
when it was reported that plasma changes in MDA are followed by changes in urinary 
MDA 24 h later [127].  Increased levels of MDA have been observed in infants born to 
mothers who went through labor as opposed to those who had elective caesarean section 
without labor [128].   
Studies measuring nitrotyrosine in hypoxic preterm infants are rare (Table 3).  
Plasma nitrotyrosine was found to be significantly higher in preterm neonates with 
bronchopulmonary dysplasia [129].  Furthermore, Hoehn et al. demonstrated that certain 
degradation products of nitrotyrosine can also be quantified in the urine of preterm 
normoxic infants [130].  Thus, it appears that nitrotyrosine can be measured in serum and 
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urine of preterm neonates.  Additional studies are needed to measure nitrotyrosine in 
hypoxic neonates to determine its utility in this context.   
 
Detecting Hypoxia Using The Biochemical Marker Lactate 
Perhaps the most commonly used biochemical marker of hypoxia is lactate.  
During anaerobic metabolism, glycolysis is sustained by the NADH-dependent reduction 
of pyruvate to lactate, yielding a net of two molecules of ATP per glucose molecule 
(Figure 2).  When the body is reoxygenated, lactate is converted back into pyruvate and 
eventually glucose in the liver at the expense of ATP (Figure 2).  The diagnostic value of 
lactate as a marker of hypoxia is controversial.  Studies suggested that lactate is a 
promising indicator of the severity of hypoxia in high-risk neonates [131] and the 
neurological outcome and mortality in severely hypoxic neonates [132, 133].  Further 
investigation into lactate as a marker of hypoxia revealed some inherent flaws.  Lactate 
levels in neonates may be increased by maternal glucose, Plasmalyte A, Ringer's lactate 
infusion or bronchodilators [134-136].  Growth-retarded infants have elevated lactate 
levels [137].  Maternal ephedrine administration can increase placental lactate production 
and alter the fetal plasma lactate level [138].  Owing to such confounding factors lactate 
may not be the most reliable marker for hypoxia.  Nevertheless, clinical lactate 
determinations are well established, while quantitation of purines is still generally limited 
to experimental settings.  Thus, lactic acid continues to be commonly used, in spite of the 
ongoing debate.    
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Lactate In Animal Models 
Owing to evidence of acidosis in cord blood of hypoxic neonates, lactate has been 
evaluated as a marker of hypoxia and asphyxia in pigs, rats, and fetal lambs (Table 4). In 
the pig model, plasma lactate levels increase linearly with tissue hypoxia, exhibiting high 
correlation with hypoxanthine during hypoxia as well as recovery [144].  In ex vivo 
experiments using pig coronary arteries, interstitial arterial wall lactate concentrations 
were observed to increase during hypoxia and fall during reoxygenation [139].  In 
asphyxiated fetal rat pups, Seidl R et al. demonstrated that lactate levels increased in the 
brain and blood compared to control animals [141].  Subcutaneous and striatal levels of 
lactate significantly increased in asphyxiated fetal rat pups, with subcutaneous lactate 
reaching a maximum around 20–21 min of asphyxia.  Similarly, striatal lactate levels 
reached a maximum around 19-20 min of asphyxia [142].  In the adult rat, arterial lactate 
levels also increased in response to hypoxia [140].  Lastly, in fetal lambs, cerebral lactate 
does not increase until there is a 30% drop in arterial oxygen saturation [143].  
 
Lactate Marker In Full-Term Neonates 
  Lactate was studied in full-term infants as a marker of hypoxia and asphyxia 
(Table 5).  A prospective study of 4045 cord samples demonstrated elevated lactate 
levels in vacuum extraction deliveries and emergency cesareans compared to standard 
vaginal delivery and  elective cesarean [145].  A correlation exists between lactate levels 
in arterial cord blood, venous cord blood and fetal scalp blood, as well as between cord 
arterial lactate, pH and base excess in infants that had ominous fetal heart rate 
patterns[146].  Lactate was evaluated in CSF and blood of neonates with hypoxic- 
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Table 4. Values of lactate in animal models. 1H-NMR: proton nuclear magnetic resonance; 
HPLC: high pressure liquid chromatography 
 
 
 
Species Method Of 
Measurement 
Source Of 
Sample 
Condition Of 
Animal 
Recorded Level Ref. 
Pig Spectrophotometric 
kinetic enzymatic 
analyzer 
Interstitium Normoxic 1.07±0.21 mmol/L [139] 
Hypoxia 
30-60 min 
2.50±0.240 mmol/L 
Adult 
Rat 
1H NMR Arterial blood 
 
 
 
Normoxic 3.6±1.6 mmol/L [140] 
Hypoxia 13.5±4.3 mmol/L 
Hypoxia 
reoxygenation 
8.3±3.3 mmol/L 
Fetal 
Rat 
Colorimetric test 
 
 
 
 
Brain 
 
 
 
 
 
Normoxic 88.55±0.78 μM/g [141] 
Asphyxia 5min 14.77±2.95. μM/g 
Asphyxia 10min 19.63±1.36 μM/g 
Asphyxia 15min 28.26±1.22 μM/g 
Asphyxia 20min 36.66±3.22 μM/g 
Enzymatic 
spectrophotometric 
end point assay 
 
 
 
Blood 
 
 
 
 
 
 
Normoxic 8.72±1.97 mM/L [141] 
Asphyxia 5min 10.35±1.15 mM/L 
Asphyxia 10min 12.10±1.59 mM/L 
Asphyxia 15min 14.24±1.30 mM/L 
Asphyxia 20min 13.34±1.84 mM/L 
HPLC 
 
 
 
 
Subcutaneous 
 
 
 
 
Normoxic 0.7 mM [142] 
Asphyxia 2-3min 1.2±0.13 mM 
Asphyxia 20-21min 2.7±0.36 mM 
Asphyxia 21-22min 1.5±0.17 mM 
Normoxic 3.5 μmol/g 
Striatum 
 
 
Asphyxia 5-6min 7±1.3 μmol/g 
19-20min 16.7±1.9 μmol/g 
  Normoxic 0.4±0.9 mmol/Kg 
Fetal 
Lamb 
Proton magnetic 
resonance 
spectroscopy 
Cerebral Hypoxic 6.7±3.6 mmol/Kg [143] 
Normoxic 88.55±0.78 μM/g 
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Table 5. Values of lactate in full-term neonates. HIE: Hypoxic-Ischemic Encephalopathy; 1H-
NMR: proton nuclear magnetic resonance; CSF: cerebrospinal fluid 
 
Method Of 
Measurement 
Source Of 
Sample 
Condition Of Patient Recorded Level  Ref. 
1H NMR Urine Normoxic ≥6hr 0.09±0.02 Lactate/creatinine [148] 
Normoxic 48-72hr 0.09±0.03 Lactate/creatinine 
Asphyxia (no HIE) ≥6h 0.19±0.12 Lactate/creatinine 
Asphyxia (no HIE) 48-72h 0.16±0.17 Lactate/creatinine 
Asphyxia (HIE) ≥6hr 16.75±27.38 
Lactate/creatinine 
Asphyxia (HIE) 48-72hr 0.92±1.77 Lactate/creatinine 
Electrochemical 
test strip method 
Arterial 
umbilical 
blood 
Standard vaginal delivery 1.87±0.94 mmol/L [145] 
Vacuum delivery 2.95±1.20 mmol/L 
Elective cesarean 1.44±0.10 mmol/L 
Emergency cesarean 2.44±0.69 mmol/L 
Roche L-640 
lactate analyze 
[149] 
CSF Normoxic  1.9±0.4 mmol/L [147] 
Asphyxiated 2.9±1.2 mmol/L 
Blood Normoxic  2.2±0.6 mmol/L 
Asphyxiated 3.9±1.1 mmol/L 
 
 
 
Table 6. Values of lactate in preterm neonates 
 
Method Of 
Measurement 
Source Of Sample Condition Of 
Patient 
Recorded Level  Ref. 
ABL Radiometer device Umbilical artery blood Normoxic 29.4±2.75 mg/dl [150] 
GM 7 analyzer Umbilical artery blood Healthy 2750±470  μmol/L       [131] 
High risk 5100±2700 
μmol/L  
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ischemic brain insult [147].  The role of lactate as a marker of neonatal stress was further 
validated when Huang et al. reported that the urinary lactate:creatinine ratio, measured 
soon after birth, may help to identify hypoxic-ischemic encephalopathy in asphyxiated 
newborns [148]. 
 
Lactate Marker In Preterm Neonates 
Despite the common use of lactate as an indicator of hypoxia in the clinical 
setting, there are few data on the relevance of lactate in preterm neonates (Table 6).  It 
was shown that umbilical artery mean lactate levels are higher in preterm infants than in 
term  infants [150].  Chou et al. also demonstrated elevated lactate levels in preterm 
infants compared to full-term ones, but this group further demonstrated elevated lactate 
levels in high-risk neonates [131].  Lastly, Groenendaal et al. have proposed that lactate 
may be an indicator of adverse outcome.  They reported that early arterial lactate levels 
were associated with a 0.47 positive and a 0.92 negative predictive value for adverse 
outcomes [151].  Further research needs to be carried out in order to validate lactate as a 
marker of hypoxia in preterm neonates. 
 
Conclusions 
Quantification of the presence and severity of fetal and neonatal hypoxia remains 
a challenge.  Identification, characterization and validation of biomarkers that swiftly 
identify neonates at risk of hypoxia-induced damage are needed.  It was suggested that 
the therapeutic window for intervention in hypoxic-ischemic neonates is approximately 6 
h following the onset of hypoxia [152].  Since the time allowed for intervention is short, 
the rapid detection of direct markers of hypoxia are needed.  Numerous biochemical 
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markers are currently being used for the identification of hypoxia [23, 153-156].  Some of 
the most promising candidates are purine metabolites, lactate, and biochemical markers 
of ROS or RNS.  These markers are primarily measured in body fluids, unlike ATP and 
inorganic phosphate, which can be measured by tissue MRI.  This review highlighted the 
use of hypoxanthine, xanthine, uric acid, xanthine oxidase, MDA, nitrotyrosine and 
lactate as biochemical markers of neonatal hypoxia.  While the assays for some of these 
markers are well established, others require further characterization [157, 158].  In 
addition, several xanthine oxidase inhibitors have been evaluated as potential agents for 
reduction of hypoxia-induced cellular damage [159-161].  With better diagnostic 
approaches to hypoxic stress, further improvements in the understanding of affected 
biochemical processes are expected and more rational interventions can be developed and 
tested. 
 
Future Perspectives 
It is speculated that within the next 5-10 years, several major developments in the 
field of biochemical markers of hypoxia will occur.  First, new biochemical markers of 
hypoxia will become established.  Allantoin, a product of oxidation of uric acid, is 
currently being investigated as a marker of hypoxia.  Allantoin increased in premature 
infants who subsequently developed chronic lung disease [162], but further research is 
needed to establish it as a marker of hypoxia.  Second, a combination of biochemical 
markers will improve predictive value for severity of tissue damage and outcome in the 
clinical setting.  For this to occur, some of the current biochemical markers of hypoxia 
need to be adapted to the clinical setting, and clinical studies using combinations of 
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markers for higher predictive value will need to be carried out.  A candidate combination 
of markers could include lactate, hypoxanthine, xanthine oxidase, and MDA.  This would 
incorporate circulatory acid/base status, purine metabolism, ROS-generating enzyme 
level and a product of lipid peroxidation into a combined evaluation of neonatal hypoxia 
and tissue damage.  Lastly, a greater understanding of the biochemical processes of 
hypoxia will enhance the development of therapeutics.  Several compounds are currently 
being investigated [159, 163]. 
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Table 7. Executive Summary 
 
EXECUTIVE SUMMARY 
Neonatal hypoxia 
 Neonatal hypoxia is a clinical condition with overt biochemical consequences.  
 This condition is associated with a high morbidity and mortality rate. 
 Hypoxia is associated with the production of reactive oxygen species (ROS), Reactive nitrogen species (RNS), 
ATP depletion and risk of developmental abnormalities and growth retardation. 
The biochemical processes of hypoxia 
 The biochemical processes of hypoxia are associated with anaerobic metabolism. 
 Anaerobic metabolism creates an energy-deprived state, forcing the breakdown of ATP ultimately to uric acid, 
and driving the formation of lactate to sustain glycolysis. 
 Purine metabolism following reperfusion requires the enzyme xanthine oxidase, which generates ROS.  
 In the brain, hypoxia triggers a series of events leading to formation of ROS and RNS. 
Clinical evaluation of hypoxia 
 Currently accepted method for diagnosis of fetal/perinatal hypoxia involves a combination of nonspecific 
approaches: Apgar score, umbilical cord pH, Sarnat staging, and fetal heart rate monitoring 
 These methods do not correlate well with the severity of hypoxia, which may be difficult to asses do to its 
numerous causes 
 Several fetal and maternal factors contribute to the onset and severity of hypoxia making it difficult to diagnose 
with the current nonspecific clinical methods 
Purine biochemical markers of hypoxia 
 Promising candidate markers for quantification of the severity of hypoxia, and prediction of its sequel, are purine 
degradation products  
 Purine biochemical markers include hypoxanthine, xanthine, uric acid, and the enzyme xanthine oxidase 
 The value of purines and xanthine oxidase as markers of hypoxia was demonstrated in animals, full-term infants 
and preterm infants 
ROS and RNS biochemical markers of hypoxia 
 Products of short-lived ROS or RNS, specifically, malondialdehyde (MDA) and nitrotyrosine, respectively, may 
serve as biochemical markers of hypoxic stress 
 MDA measurements are a commonly used indicator of oxygen induced free radical damage. 
 Cerebrospinal fluid nitrotyrosine levels were used as a reliable predictor of poor neurological outcome in adults, 
making it of key interest in correlating severity of hypoxia damage with outcome in neonates. 
Lactate as a marker of hypoxia 
 Lactate is one of the most commonly used biochemical markers of hypoxia and it is formed during anaerobic 
metabolism to support glycolysis. 
 The diagnostic value of lactate as a marker of hypoxia is controversial due to evidence that lactate may also be 
increased by maternal glucose, Plasmalyte A, Ringer's lactate infusion or bronchodilators. 
 Despite the controversy, studies have indicated that lactate is a promising predictor of the severity of hypoxia in 
high-risk neonates and the neurological outcome and mortality in severely hypoxic neonates. 
Conclusion 
 Identification, characterization and validation of biomarkers that swiftly identify neonates at risk of hypoxia-
induced damage are needed. 
 Detection of the presence and evaluation of severity of fetal and neonatal hypoxia remains a challenge. 
 Better diagnostic approaches to hypoxic stress will further improve the understanding of affected biochemical 
processes and lead to more rational interventions. 
Future prospective 
 It is speculated that within the next 5-10 years, several major developments with biochemical markers of hypoxia 
will occur. 
 First, new biochemical markers of hypoxia will be established. 
 Second, a combination of biochemical markers will improve the predictive value for severity of tissue damage and 
outcome in the clinical setting. 
 Lastly, improved understanding of the biochemical processes of hypoxia will enhance the development of 
therapeutics. 
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Abstract 
Neonatal hypoxia ischemia is characterized by inadequate blood perfusion of a 
tissue or a systemic lack of oxygen.  This condition is thought to cause/exacerbate well 
documented neonatal disorders including neurological impairment [1-3].  During 
hypoxia, aerobic metabolism is switched to anaerobic pathways.  Decreased adenosine 
triphosphate production occurs due to a lack of oxidative phosphorylation.  To 
compensate for this energy deprived state molecules containing high energy phosphate 
bonds are degraded [2].  This leads to increased levels of adenosine, which is 
subsequently degraded to inosine, hypoxanthine, xanthine, and finally to uric acid.  The 
final two steps in this degradation process are performed by xanthine oxidoreductase. 
This enzyme exists in the form of xanthine dehydrogenase under normoxic conditions but 
is converted to xanthine oxidase (XO) under conditions of hypoxia-reperfusion [4, 5].  
Unlike xanthine dehydrogenase, XO generates hydrogen peroxide as a byproduct of 
purine degradation [4, 6].  Hydrogen peroxide, in combination with other reactive oxygen 
species (ROS) produced during hypoxia, oxidize uric acid to form allantoin and react 
with lipid membranes to generate malondialdehyde (MDA) [7-9].  Most mammals, 
humans exempted, possess the enzyme uricase, which converts uric acid to allantoin.  In 
humans, however, allantoin can only be formed by ROS-mediated oxidation of uric acid. 
Because of this, allantoin is considered to be a marker of oxidative stress in humans, but 
not in the mammals that possess uricase. 
We describe methods employing high-pressure liquid chromatography (HPLC) 
and gas chromatography mass spectrometry (GCMS) to measure biochemical markers of 
neonatal hypoxia ischemia.  Human blood is used for most tests.  Animal blood may also 
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be used while recognizing the potential for uricase-generated allantoin.  Purine 
metabolites were linked to hypoxia as early as 1963 and the reliability of hypoxanthine, 
xanthine, and uric acid as biochemical indicators of neonatal hypoxia was validated by 
several investigators [10-13].  The HPLC method used for the quantification of purine 
compounds is fast, reliable, and reproducible.  The GCMS method used for the 
quantification of allantoin, a relatively new marker of oxidative stress, was adapted from 
Gruber et al. [7].  This method avoids certain artifacts and requires low volumes of 
sample.  Methods used for synthesis of MMDA were described elsewhere [14, 15]. 
GCMS based quantification of MDA was adapted from Paroni et al. and Cighetti et al. 
[16, 17].  Xanthine oxidase activity was measured by HPLC by quantifying the 
conversion of pterin to isoxanthopterin [18].  This approach proved to be sufficiently 
sensitive and reproducible. 
 
Protocol 
Sample Collection And Processing 
Collect blood sample in a 6ml K3E EDTA K3 tube which is kept on ice.  Within 2 
min of collection, centrifuge the sample at 4oC at 1500 g for 10 min.  Transfer the 
supernatant (plasma) to a 1.5ml microcentrifuge tube.  Centrifuge at 4oC at 18000 g for 
30 min.  Remove the supernatant and transfer into separate microcentrifuge tubes for 
purine (200μl), allantoin (50μl), MDA (100μl), and XO (120μl) analysis.  Be careful not 
to contaminate the samples with red blood cells.  You may need to adjust the volumes of 
plasma for MDA, XO, and purines based upon the total volume of plasma available.   
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Table 1: Solvent changes for HPLC measurement of purine compounds. 
 
 Time Flow (ml/min) %A %B %C 
1  1.00 0.0 0.0 100.0 
2 16.00 1.00 0.0 0.0 100.0 
3 17.00 1.00 100.0 0.0 0.0 
4 22.00 1.00 100.0 0.0 0.0 
5 27.00 1.00 0.0 100.0 0.0 
6 32.00 1.00 0.0 100.0 0.0 
7 33.00 1.00 100.0 0.0 0.0 
8 38.00 1.00 100.0 0.0 0.0 
9 39.00 1.00 0.0 0.0 100.0 
11 45.00 1.00 0.0 0.0 100.0 
 
 
 
 
 
 
 
 
 
 
Table 2: Typical retention times and  max for purines and internal standard. *Determined on 
HPLC using isocratic 50mM ammonium formate buffer (pH 5.5) with a flow rate of 1mL/min. 
pH is in ( ). 
 
 Retention Time* Observed max* Reported 
max[19] 
   Reported 
max[19] 
Uric Acid ~ 3.5 min 288  283 (2) 11,500 (2) 
Hypoxanthine  ~7.0 min 248  248 (1) 10,800 (1) 
Xanthine ~ 9.5 min 267 267 (2) 10,200 (2) 
2-Aminopurine ~ 12.5 min 305  314 (2) 4000 (2) 
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described in Table 1 should be used to obtain adequate peak separation: solvent A-water, 
solvent B- methanol, solvent C- 50mM ammonium formate buffer, pH 5.5.  Determine 
the concentration of purines in the sample.  Quantify hypoxanthine, xanthine, and uric 
acid by obtaining peak areas at the retention times and wavelengths described in Table 2.  
Determine the peak area of 2-AP.  Determine the area ratios of hypoxanthine, xanthine, 
and uric acid to 2-AP and convert the ratios to µmolar concentrations using standard 
curves.  Analyze all samples in triplicate, but only include values for later analyses if the 
coefficient of variation is less than 10%. 
 
GCMS Measurement Of Allantoin 
Add 50μl of 10μM DL-Allantoin-5-13C;1-15N (internal standard) to the 50 μl 
plasma set aside for the allantoin assay during sample collection and processing.  Add 
100 μl acetonitrile to this plasma solution.  Vortex the mixture for 10-20 sec then 
centrifuge at 4oC at 20000 g for 10 min.  Transfer the supernatant to a GCMS vial and 
dry under N2.  After drying, Resuspend in 50 μl of derivatizing agent N-tert-
Butyldimethylsilyl-N-methyltrifluoroacetamide (MTBSTFA) in pyridine (1:1 vol/vol), 
cap the vials and incubate at 50oC for 2 h.  This derivatization yields consistently 
quantifiable m/z peaks of 398.0 and 400.0 for allantoin and DL-Allantoin-5-13C;1-15N 
respectively [20].  Analyze samples on a GCMS equipped with an auto sampler.   
Perform compound separation on an Agilent 122-5532G capillary column (25.7m 
length, 0.25mm internal diameter).  Use helium as the carrier gas at a flow rate of 1.5 
ml/min.  Inject derivatized product (1 µl) in split mode (split ratio 20:1, split flow 29.4 
ml/min, total flow 33.8 ml/min).  Set the initial column temperature at 100oC and hold at 
62 
that temperature for 2 min before increasing it to 180oC at a rate of 10oC/min.  Hold the 
temperature for 4 min and then increase it to 260oC at a rate of 20oC/min.  Maintain this 
temperature until the end of the run.  After each sample, clean the column with 1 
injection of acetonitrile and 2 injections of MTBSTFA in pyridine (1:1 vol/vol).  
Quantify allantoin using select ion monitoring mode while monitoring the 398.00 m/z ion 
for allantoin and the 400.00m/z for the DL-allantoin-5-13C;1-15N.  Convert the ion 
abundance ratios of allantoin/(heavy allantoin) to micromolar concentrations of allantoin 
using a prepared standard curve.  All samples are analyzed in triplicate but only values 
with a coefficient of variation of less than 10% are used in further analyses. 
 
Preparing Internal Standard, Methyl Malondialdehyde (MMDA), For 
MDA Analysis 
Add 523μl of 3-ethoxymethacrolein and 1477μl of 7M NaOH to a 100ml round 
bottom flask.  Add a stirbar.  Place the flask in a water bath at 45oC and stir until the 
reaction has gone to completion.  This should take roughly 140 min.  Monitor the 
progress of the reaction by removing 10μl of liquid from the flask periodically, around 10 
min intervals.  Dilute each sample collected to a factor of 105 using 50 mM potassium 
phosphate buffer (pH 7) and measure the absorbance on the UV-Vis.  Once the 
absorbance at 275nm reaches roughly 0.658 the reaction is complete.  As the reaction 
progresses, the solution will turn yellow then orange.  Allow the reaction to progress for 
an additional 15 min.  Add 5ml of distilled deionized water to the round bottom flask and 
transfer the solution to a separatory funnel.  Use an additional 5 ml of water to wash the 
contents of the flask into the funnel.  Extract the solution 3 times with 5 ml 
dichloromethane.  After each extraction discard the organic layer.  After the third 
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extraction, transfer the aqueous layer to a round bottom flask and rotovap to dryness.  
Resuspend the product in 3ml ethanol and transfer to a pre-weighed 15ml conical tube.  
Rinse the flask with an additional 2ml of ethanol and add the rinse to the conical tube.  
Add 5ml benzene and incubate the tube in warm water until the product dissolves then 
immediately place the tube on ice for 10 min.  Centrifuge for 5 min at 15000 g and 
remove the supernatant.  Add 5ml ethanol and 5 ml isopropyl ether to the precipitant.  
Dissolve the precipitant by incubating the tube in warm water and periodically tilting the 
tube very gently.  Once precipitate is dissolved, place the tube on ice for 10 min.  Perform 
this recrystallization 2 more times with ethanol and isopropyl ether.  Some insoluble 
white chunks of product may be formed.  After the last recrystallization step remove as 
much supernatant as possible and dry the resultant product in a Speedvac.  Weigh the 
conical tube with the synthesized product.  Add 5ml water to the tube, vortex, and filter 
out any remaining solids.  Use the UV-vis spectrophotometer to determine the final 
concentration of MMDA.  The λmax for MMDA in 50 mM potassium phosphate buffer 
(pH 7) is 274 nm with the extinction coefficient of 29900 M-1cm-1 [14]. 
 
GCMS Measurement Of MDA 
Prepare a solution of 0.5mM butylated hydroxyl toluene (BHT) in ethanol by 
adding 0.11 g BHT to 9ml ethanol and adjusting the final volume to 10ml.  Then perform 
a dilution by adding 10μl of this concentrated solution to 990μl ethanol.  Prepare a 
solution of 50mM phenyl hydrazine by adding 4.92μl of phenyl hydrazine to 995μl of 
water in a dark microcentrifuge tube.  Vortex the solution.  Add 5μl 10μM MMDA to the 
100μl plasma set aside for the MDA assay during sample collection and processing.  
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Then add 10μl 0.5mM BHT to the MMDA/plasma mixture fallowed by the addition of 
200μl 1M sodium citrate (pH 4).  This pH is crucial for correct derivatization of the 
sample.  A higher or lower pH will result in skewed MDA levels.  Dilute the final 
mixture by adding distilled deionized water to a final volume of 480μl.  Derivatize the 
solution by adding 20μl 50mM phenyl hydrazine, capping the vials, and incubating the 
solution at 25oC for 30 min on an orbital shaker.  Add 1ml of hexane, vortex for 1 min, 
and centrifuge at 3000 rpm for 10 min.  Transfer the organic layer to a GCMS vial and 
concentrate the solution to 100μl by N2 stream. 
Analyze samples on a GCMS using the auto sampler.  Perform compound 
separation on an Agilent 122-5532G capillary column (25.7 m length, 0.25 mm internal 
diameter).  Use helium as the carrier gas at a flow rate of 0.6-0.8 ml/min.  Inject 
derivatized product (2 µl) in split mode (split ratio 20:1, split flow 23.0 ml/min, total flow 
27.1 ml/min).  Set the initial column temperature at 110oC and hold at that temperature 
for 1 min before increasing it to 250oC at a rate of 40oC/min.  Maintain this temperature 
until the end of the run.  After each sample, clean the column with 2 injections of hexane.  
Quantify MDA using select ion monitoring mode using the 144.00 m/z for MDA and the 
158.00 m/z for MMDA.  Convert the MDA/MMDA ion abundance ratios to micromolar 
concentrations using a standard curve.  Analyze samples in triplicate and only use values 
with a coefficient of variation of less than 10%. 
 
HPLC Measurement Of Xanthine Oxidase 
The detection of xanthine oxidase function is dependent on the ability to 
sensitively measure the levels of a suitable substrate (pterin) as well as its product 
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(isoxanthopterin).  Plasma is incubated with the substrate either for 0 min (control) or 4 h, 
and the incubation-dependent substrate conversion is determined.  Add 240μl 0.2 M Tris-
HCl buffer (pH 9.0) and 4.63μl 7.083x10-3 M pterin to each tube (0 and 4h) and 
preincubate them at 37oC for 5 min.  Initiate the enzyme reaction by adding 60μl of 
plasma to each tube.  Immediately add 300μl 4% HClO4 to the 0 incubation tube but 
allow the other mixture to incubate for 4 hours before quenching the reaction with 300μl 
4% HClO4.  After the addition of HClO4, vigorously shake the tube and then centrifuge at 
4oC at 15000 g for 15 min.  Remove 500μl of supernatant and neutralize by adding 20μl 
of 5M K2CO3.  Vigorously shake the tube and then centrifuge at 4
oC at 15000 g for 15 
min.  Add 350μl of the neutralized solution to a microcentrifuge tube containing 1x10-8 
mol 2-AP.   
Analyze samples on an HPLC equipped with a scanning fluorescence detector.  
Three 50 µl injections are used for each sample.  Samples will be injected onto a Wacosil 
5C-18-200 250 mm x 6.0 mm, 5 µm column equipped with a Supelguard LC-18-S 
column guard.  The following isocratic conditions should be used to obtain adequate peak 
separation and identification: 95% 20mM KH2PO4 buffer (pH 2.2) and 5% methanol at a 
flow rate 1ml/min.  Set the excitation wavelength for the fluorescence detector at 345 nm 
and the emission wavelength at 410 nm.  Determine the ratios of pterine and 
isoxanthopterine to 2-AP by obtaining peak areas from the fluorescence detector 
spectrum.  The first peak in the spectrum, ~ 5 minutes, corresponds to 2-AP.  The second 
and largest peak will be pterine.  Isoxanthopterine peak elutes last.  Obtain the difference 
in the isoxanthopterine/2-AP peak area ratios between the 0 and the 4 h incubation time 
66 
points.  Use this value to calculate the XO activity from standard curves.  Analyze 
samples in triplicates but use only values with a coefficient of variation of less than 10%. 
 
Representative Results 
An example of the HPLC quantification of purine compounds is shown in Figure 1A.  
The specific retention times and emission wavelengths of hypoxanthine, xanthine, and 
uric acid permit the simultaneous quantification of purine compounds (Table 2).  When 
the assay is run correctly, the compounds will have adequate separation and the peak 
shape will be sharp and unimodal.  These peaks are then converted into concentrations, 
ranges shown in table 3, through the use of a standard curve.  Because sample processing 
for this assay is minimal, the only sample based problems which may arise would be the 
lysing of the red blood cells.  If the red blood cells lyse before the samples are 
centrifuged, the plasma will take on an orange/red color and cannot be used for 
evaluating hypoxic ischemia.  The other issues which may arise when measuring purines 
involves the HPLC system and the column (Figure 1B).  If there are air bubbles in the 
HPLC system the retention times will shift and the HPLC pressure will fluctuate 
dramatically.  If the guard cartridge needs to be changed, the pressure will increase and 
the peaks will widen and become bi or tri-modal. 
 An example of the GCMS quantification of Allantoin is shown in Figure 
2.  Because the mass of derivatized allantoin and derivatized heavy allantoin is known, 
select ion mode can be used to identify these compounds on the GCMS.  If the assay is 
done correctly, two peaks will be observed at the same retention time.  One 
corresponding to allantoin (398.00 m/z) and the other to heavy allantoin (400.00 m/z).  
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These peaks are then converted into concentrations, ranges shown in table 3, through the 
use of a standard curve.  If the assay is run incorrectly, and samples were not derivatized 
properly, the peaks may not be present or may not be quantitatively representative.  Once 
again, if the red blood cells lysed the plasma cannot be used to evaluate oxidative stress 
in neonatal hypoxic ischemia. The results for the quantification of MDA are similar to 
those for allantoin with the exception that the two peaks are observed at different 
retention times.  At  ~ 3 minutes retention time, a 144.00 m/z peak for MDA and at ~3.5 
minutes retention time, a 158.00 m/z peak for MMDA is observed (Figure 3).  These 
peaks are then converted into concentrations, ranges shown in table 3, through the use of 
a standard curve.  If the assay is run incorrectly, or samples are not derivatized properly, 
no peaks may be observed when selecting for 144.00m/z and 158.00m/z.  It should be 
noted that if there is an excess of lipid in the plasma from bolus oral feedings or 
intravenous lipid administration, the plasma will take on a milky appearance and cannot 
be used to evaluate oxidative stress in neonatal hypoxic ischemia. 
An example of the HPLC-based quantification of xanthine oxidase function is 
shown in Figure 4.  If the assay is run correctly, three peaks should be observed with the 
fluorescent detector, one for pterin, one for isoxanthopterine, and one for 2-AP.  These 
peaks are then converted into concentrations, ranges shown in table 3, through the use of 
a standard curve.  There should also be a peak corresponding to isoxanthopterin and 2-AP 
on the spectrum generated from the PDA detector.  If the enzyme activity is absent, the 
peak corresponding to isoxanthopterin will not be seen.  Because this assay measures 
enzyme function, repeated freezing and thawing of the sample may alter this 
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Figure 1: HPLC Chromatogram for the Identification of Purine Compounds. A). 
Representative results if the assay was run correctly. B). Representative results if there is a 
problem with the HPLC, column, or guard cartridge.   
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Table 3: Representative ranges for purines, xanthine oxidase, malondialdehyde, and 
allantoin. Max-Min (n). 
 
  Hypoxanthine Xanthine Uric Acid 
Xanthine 
Oxidase MDA Allantoin 
Term 
Normoxic  
1.13-19.3 
(n=64) 
0.02-3.69 
(n=61) 
107.20-726.12 
(n=63) 
2.47x10-6 - 
3.92x10-3 
(n=20) 
0.44-3.76 
(n=53) NA 
Term 
Respiratory 
Distress 
1.78-12.59 
(n=27) 
0.07-11.8 
(n=24) 
225.40-653.32 
(n=27) 
0 - 1.03x10-5 
(n=8) 
0.82-2.73 
(n=24) NA 
Term 
Hypoxic 
0.38-31.80 
(n=13) 
0.11-2.88 
(n=13) 
235.65-
1348.13 
(n=13) 
1.20x10-5 -
236.44 (n=9) 
0.95-2.15 
(n=7) NA 
Preterm 
Normoxic  
1.54-4.39 
(n=9) 
0.03-1.77 
(n=9) 
178.92-593.49 
(n=9) 
2.46x10-5 - 
5.44x10-4 (n=2) 
0.95-2.74 
(n=8) 
2.30-5.26 
(n=67) 
Preterm 
Respiratory 
Distress 
3.04-8.04 
(n=2) NA 
327.56-365.11 
(n=2) NA 
2.40-3.46 
(n=3) NA 
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      Figure 2:  GCMS Spectrum for the Quantification of Allantoin.   
 
 
 
 
 
17.16  Heavy Allantoin 
Allantoin 
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     Figure 3: GCMS Spectrum for the Quantification of MDA.   
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Figure 4: HPLC spectrum for the measurement of XO activity.  A).  Representative results 
for the 0 min incubation time and B) Representative results for the 4 hour incubation time.  Note 
the higher isoxanthopterine peak for the 4 hour incubation time.   
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Discussion 
The methods described here permit for the evaluation of neonatal hypoxic 
ischemia.  This protocol combines the measurements of markers of energy deprivation, 
oxidative stress, oxidative damage, and enzyme activity to gain an overall biochemical 
picture of the presence or even the degree of hypoxic ischemia.  Despite the usefulness of 
this method, there are potential limitation.  First, it takes roughly 1-2 ml of blood to 
collect enough plasma to run all of the assays.  This will not be a problem in adults or 
children, but it poses issues when it comes to term and especially preterm neonates.  We 
work around this issue by prioritizing assays and diluting some of the samples if 
necessary.  Secondly, it can be difficult to synthesize MMDA; however, deuterated MDA 
can be used as a substitute for MMDA as an internal standard.   
Despite these minor limitation, the method described here provide a useful tool in 
evaluating neonatal hypoxic ischemia as well as other diseases associated with alterations 
in redox homeostasis.  Moreover, all of these markers, with the exception of XO, can be 
measured in urine, providing a non-invasive means of monitoring neonates.   
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Abstract 
Infants exposed to common neonatal intensive care unit (NICU) procedures show 
alterations in heart rate, blood pressure and oxygen saturation; however, it is unclear if 
these physiologic changes increase adenosine triphosphate (ATP) utilization, thus 
potentially increasing the risk for tissue hypoxia in medically fragile neonates.  Plasma 
uric acid is a commonly used marker of increased ATP utilization because uric acid 
levels increase when ATP consumption is enhanced.  To examine the effect of a common 
NICU procedure on plasma uric acid concentration, we developed a model that allows for 
acute monitoring of this biochemical marker in plasma in 7- to 9-day-old rabbits.  In this 
pilot study, we exposed neonatal rabbits to a single heel lance 2.5 hr after catheter 
placement.  We measured uric acid concentration before and 30 min after the heel lance 
and compared findings to levels in control animals not exposed to the heel lance.  Our 
pilot data shows a significant difference in uric acid concentration over time between the 
control and heel lance groups (46.27.1 M vs. 54.75.8 M, respectively, P = 0.027). 
Calculation of percent change from baseline showed uric acid concentration increasing in 
rabbits exposed to heel lance and decreasing in control rabbits (1.5%4.7% vs. -
16.14.2%, respectively, P= 0.03).  These data suggest that this animal model can be 
successfully used to examine the biochemical effect of common NICU procedures, such 
as heel lance, on markers of ATP breakdown and purine metabolism. 
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Introduction 
Infants in the neonatal intensive care unit (NICU) routinely undergo painful and 
invasive procedures.  NICU patients are exposed to an average of 12 ± 8 painful 
procedures per day and 141 ± 107 total procedures over a 14-day period [1].  Invasive 
and painful NICU procedures are known to alter physiological homeostasis by increasing 
heart rate and metabolism and decreasing oxygen saturation and transcutaneous PaO2 
(partial pressure of oxygen in arterial blood) [2, 3].  However, it is unclear if painful 
procedures increase adenosine triphosphate (ATP) utilization in excess of ATP synthesis, 
increasing the risk for tissue hypoxia.  Pilot data from our laboratory demonstrated 
significant alterations in purine metabolism in the plasma of premature neonates 
experiencing tape removal, while a recent paper by Bellieni and colleagues showed an 
increase in markers of oxidative stress in the plasma of premature neonates experiencing 
heel lance [4, 5].  These data suggest that common NICU procedures can lead to 
enhanced ATP breakdown and oxidative stress in immature neonates. 
To further examine the biochemical effects of commonly performed NICU 
procedures, our laboratory developed a neonatal rabbit model for acute monitoring of 
ATP breakdown and purine metabolism.  The neonatal rabbit kit is an ideal NICU model 
for several reasons.  First, the neonatal rabbit kit has brain development similar to the 
premature human neonate, with a high cortical white:gray matter ratio and undeveloped 
cerebral white matter with undefined masses of neuroblasts [6] These similarities enable 
evaluation of the white matter injury commonly seen in hypoxic premature neonates. 
Second, unlike rats or mice, neonatal rabbits are unique in that maternal behavior is 
restricted and minimal, making it possible to perform procedures and obtain results that 
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are independent of stresses related to maternal separation, feeding behavior or 
interference [7].  Lastly, the larger size and higher plasma volume of the postnatal rabbit 
kit at age 7–9 days when compared to the postnatal rat or mouse of the same age, 
approximately 15 times bigger than the neonatal rat pup, makes it possible to monitor 
heart rate, oxygen saturation and blood pressure during procedures as well as collect 
multiple blood samples from each animal without causing hypovolemia and significantly 
altering cardiovascular homeostasis.  
Based on the above-described characteristics, we examined the possible use of 
neonatal rabbits as an experimental model to measure the effect of commonly performed 
NICU procedures on ATP breakdown.  It is well documented that when animals and 
humans are challenged with increased metabolic needs, they will catabolize high-energy 
phosphate bonds such as ATP [8-13].  The degradation of ATP results in increased levels 
of free adenosine, which is consequently degraded to inosine and then to hypoxanthine 
and xanthine and finally to uric acid (Figure 1).  In humans, an increased level of uric 
acid is a commonly accepted biochemical marker of hypoxia-ischemia and increased 
ATP breakdown [8, 11, 13].  If common NICU procedures enhance ATP and purine 
consumption, we would expect to see a significant increase in the concentration of 
markers of ATP utilization, specifically uric acid, in rabbit kits exposed to procedures 
commonly performed in the NICU.  
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Figure 1. Exposure to neonatal intensive care unit (NICU) procedures/pain leads to adenosine 
triphosphate (ATP) breakdown and uric acid metabolism. O2 = oxygen. 
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Methods 
Animals 
We performed all experiments in accordance with approved institutional animal 
care guidelines.  We purchased midgestation New Zealand rabbit dams from a local 
vendor and allowed them to deliver naturally at term.  At postnatal day of life 5, we 
transported the rabbit dam and kits to the animal care facility, where they were 
maintained under approved laboratory conditions.  Animals were housed in a steel cage 
with a thermoregulated litter box containing nesting materials for the kits.  Food and 
water were made available ad libitum. 
 
Central Catheter Placement 
We performed catheter placement on a warming pad and facilitated dissection 
using an OPMI-6 surgical microscope (Karl Zeiss Co., Germany) at approximately 10X 
magnification.  We fashioned the catheters by inserting and gluing PE-10 tubing 
(Braintree, MA) into PE-50 tubing (Braintree, MA) prior to sterilization.  At postnatal 
day of life 7–9, neonatal rabbit kits were quickly anesthetized with 3%–3.5% isoflurane 
and then maintained by mask ventilation with 1.5%–2.5% isoflurane to maximize 
anesthesia while minimizing cardiorespiratory depression.  Once the kits were 
anesthetized, we made an incision in the neck to the right of the ventral midline and 
isolated the internal jugular vein from surrounding tissue.  We made a second skin 
incision inferior to the left scapula and tunneled a venous catheter subcutaneously from 
the back incision to the neck incision.  We then inserted a 25-gauge butterfly into the free 
end of the PE-50 tubing and filled the catheter with heparinized saline (20 units/ml).  We 
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ligated the distal internal jugular vein with 8-0 ophthalmic nylon and made a venotomy 
with a 25-gauge needle.  We then passed the catheter antegrade through the venotomy at 
a predetermined distance to reside at the junction of superior vena cava and right atrium. 
We secured the catheter to the proximal vein using 6-0 silk after ensuring patency, filled 
it with heparinized saline, and locked it with gentamicin (120 microgram/ml).  We closed 
subcutaneous tissues in a routine manner with 6-0 vicryl and maintained catheter patency 
by flushing with heparinized saline (10 units/ml) after each blood draw, as described 
below.  We employed standard aseptic techniques and monitored the rabbit kits 
continuously for heart rate, respiratory rate and temperature.  After completing the 
catheterization procedures, we discontinued anesthesia.  All rabbit kits recovered 
immediately and were observed to be active and moving freely within 15–30 min. They 
remained awake (unanesthetized) and active for the duration of the study. 
 
Blood Sampling Procedure For Acute Monitoring Of Plasma Uric Acid Concentration 
  To examine the effectiveness of this animal model in acutely measuring the 
effects of common NICU procedures on plasma uric acid concentration, we randomized 
rabbit kits to either a time-control or a heel lance group.  We used data gathered from the 
time-control group to determine the optimal timing of the heel lance procedure in the 
experimental animals as described below.  For all animals, we drew blood from the 
jugular catheter at specific time points: immediately after catheter insertion (0 hr) and at 2 
hr, 2.5 hr and 3 hr after insertion (Figure 2).  Study conditions (lighting, noise,  
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Figure 2. Time line of experimental procedures. 
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temperature) were similar during both time-control and heel lance procedures.  Animals 
in the time-control group were allowed to move around the cage freely for the entire 
study after catheter placement; animals in the heel lance group were allowed to move 
freely until 2.5 hr after surgery when they were exposed to the heel lance procedure. 
 
Heel Lance Procedure. 
Based on data gathered in the time-control animals (see “Results,” Figure 3), we 
exposed rabbit kits in the heel lance group to heel lance (Accuchek, Roche Diagnostics 
Basel, Switzerland) at 2.5 hr after anesthesia and catheterization.  We used a lance depth 
of 2.3 mm for each heel lance procedure due to the presence of fur on the rabbit’s heel 
and to ensure that the procedure would lead to a visible single drop of blood.  
 
Blood Processing And Uric Acid Analysis 
Each blood sample was collected into an EDTA tube in the surgical sweet and 
transported it to a lab in the department, on ice, where lab personnel placed the samples 
into a Fisher Scientific AccuSpin 1R Centrifuge (Fair Lawn, NJ).  Samples were 
centrifuged for 20 min at 1,500 g and 4oC.  The plasma was removed, transferred to 
separate Eppendorf tubes and centrifuged in a Beckman Microfuge 22R centrifuge 
(Fullerton, CA) for 30 min at 18000 g, 4oC.  Each supernatant, 250µl, was then 
deproteinated using a Microcon centrifugal filter device (Millipore Corp., Bedford, MA) 
with a 10K molecular weight cutoff by spinning the loaded device for 90 min at 14000 g 
and 4oC.  Filtrate was removed and 200 µl were transferred to an Eppendorf tube 
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containing 1X10-7 mol of 2-aminopurine as internal standard.  Samples were stored at -
80oC until analysis.  
For measurement of uric acid, each blood sample was analyzed using high 
pressure chromatography (HPLC; Waters 600E, Waters 996 PDA, Millipore Corp.) by 
injecting 50 µl of sample onto a Supelcosil LC-18-S 15cm X 4.6 mm, 5 µm column 
(SGE: Austin, TX) with the following isocratic conditions: 50mM ammonium formate 
buffer, pH 5.5, flow rate 1.0 ml/min.  Uric acid and the internal standard, 2-aminopurine, 
were quantitated by obtaining peak areas at the appropriate retention times (~3.0 and 
~12.0 min, respectively) and absorbance wavelengths (288 and 305, respectively).  The 
area ratio of uric acid to 2-aminopurine was determined and converted into concentration 
using standard curves.  Samples were analyzed in triplicate and values with a coefficient 
of variation less than 10% were included in the final analysis.  
 
Statistical Analyses 
We assessed assumptions of normality and equal variance.  We used independent 
samples t-test to analyze continuous data and reported them as the mean and standard 
.  We assessed repeated measures ANOVA for one between-
subject factor (group) and one within-subject factor (time) to evaluate the effect of the 
two procedures (control vs. heel lance) on plasma uric acid concentration over time using 
interaction terms in the general linear model.  We calculated percent change in uric acid 
between 0-min (baseline) and 30-min (postprocedure) values as follows (Eq. 1):  
 
([30 min] – [0 min])/[0min]) x 100     Eq. 1 
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We performed all statistical analyses using SPSS Statistics for Windows Version 19 and 
considered differences to be significant at p < .05. 
 
Results 
Central Catheter Placement 
Using the jugular vein, we were successful in obtaining multiple blood samples 
from a total of 11 out of 15 rabbit kits (73% success rate), 5 of which were in the control 
group and 6 of which were in the heel lance group.  We were not able to obtain multiple 
blood samples in the other 4 rabbits due to catheter dislodgement or failure of the line to 
draw, possibly due to kinking or clotting. 
 
Stabilization Of Plasma Uric Acid Concentration Post Central Catheter 
Placement 
  We measured uric acid concentrations in plasma over multiple time points to 
determine when this marker stabilized after jugular catheterization.  We found in 5 
control rabbit kits that uric acid values began to fall at the 2.5- and 3-hr time points, 
suggesting achievement of steady-state ATP metabolism (Figure 3).  Thus we 
determined that the 2.5-hour time point could be used to explore the effect of procedures 
on biochemical markers of ATP breakdown.  
 
Effect Of Heel Lance On Uric Acid Levels 
  We found significant differences in uric acid concentration over a 30 min time 
period between the control group and the heel lance group (46.2  7.1 M vs. 54.7  5.8 
M, respectively, p = .027; Figure 4).  Whereas uric acid concentration decreased over 
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Figure 3. Uric acid concentration time course in control rabbit kits (n = 5; mean±SD). 
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time in control rabbits, it increased over time in rabbits exposed to heel lance (repeated 
measures, p < .05; Figure 4).  Calculation of percent change from baseline confirmed 
that uric acid concentration was increasing in the heel lance group while decreasing in the 
control group (1.5%  4.7% vs. -16.1  4.2%, respectively, p =  .03). 
 
Discussion 
Our preliminary work showed that neonatal rabbits can successfully be used as a 
model for acutely monitoring the effects of common NICU procedures on ATP 
metabolism and breakdown.  After collecting blood at four different time points post 
catheter placement, we observed that plasma uric acid levels began decreasing at the 2.5- 
and 3-hr time points.  This decrease was most likely due to the enzymatic conversion of 
uric acid to allantoin or to urinary excretion, which is to be expected in control rabbits.  
In the absence of enhanced ATP breakdown, plasma uric acid levels will gradually 
stabilize or decrease [14].  The conversion of uric acid to allantoin occurs through the 
action of uricase, an enzyme present in rabbits [15, 16].  
At the 2.5- and 3-hr mark, we noted an opposite trend in rabbits exposed to a 
single heel lance (Figure 4).  This increase in plasma uric acid concentration suggests 
that this common procedure can increase ATP utilization and breakdown.  It is unclear if 
this increase in energy needs will exacerbate hypoxia in sick premature neonates.  Further 
studies are needed to determine if enhanced ATP utilization due to exposure to common 
NICU procedures induces a hypoxic response, which may lead to inflammation and 
organ damage [17, 18]. 
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Figure 4. Differences in uric acid concentration over time in rabbits without heel lance (control 
group, n = 5) and rabbits subjected to heel lance (heel lance group, n = 6). *Repeated measures  
ANOVA. 
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One comment regarding difficulties we encountered in the use of this animal 
model might be helpful for future investigators.  After evaluating several potential sites 
for central catheter placement, we found the highest success with the internal jugular 
vein.  Although attempts to insert catheters into the femoral vein were moderately 
successful, the catheters fell or kinked when the rabbits recovered from surgery and were 
permitted to move around freely.  We disregarded other potential catheter insertion sites, 
such as the ear vein or the cephalic vein, because of vessel size and high incidence of 
vessel collapse when a sample is being aspirated.  Even with the choice of the internal 
jugular vein, only 11 of the 15 catheters placed remained patent and allowed for repeated 
blood draws. 
Our pilot study shows preliminary data documenting the use of this animal model 
to examine the relationship between a single commonly performed NICU procedure, heel 
lance, and markers of ATP breakdown.  The model could also be used to study the 
biochemical effects of a combination of NICU procedures performed sequentially, 
leading to an examination of the biochemical effects of repetitive pain- or non-pain-
inducing procedures.  The rabbit’s larger size relative to rats and mice would allow the 
measurement of other relevant biochemical markers of hypoxia, ATP breakdown or 
oxidative stress, including plasma concentrations of ATP, adenosine diphosphate (ADP), 
adenosine monophosphate (AMP), adenosine, malondialdehyde or F2 isoprostane. 
Although not performed in this current study, future investigators could develop and 
validate measures of pain specific to neonatal rabbits for use in rabbits exposed to painful 
procedures, which would allow for the examination of the relationships among 
biochemical markers of ATP utilization, hypoxia and behavioral markers of pain. 
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Because the animals survive the catheterization and blood sampling procedure, the model 
could also be used to investigate the possible link between procedural pain, increased 
ATP utilization and organ impairment, such as white matter injury, through magnetic 
resonance imaging and spectroscopy.  
 
Relevance To Nursing Practice And Research 
NICU nurses perform many painful and nonpainful procedures on the neonates in 
their care.  Although the effects of these procedures on heart rate and oxygen saturation is 
clearly visible at the bedside, it is unclear whether these alterations increase ATP 
utilization and decrease ATP synthesis, potentially increasing the risk of tissue hypoxia in 
fragile neonates.  Researchers have hypothesized that hypoxia from pain and stress 
during many weeks and months in the NICU may be one contributing factor to white 
matter injury.  However, this link remains speculative because the mechanisms that link 
pain with organ damage remain elusive.  Use of this model may help elucidate the 
relationship between single, multiple or repetitive NICU procedures and ATP breakdown 
and hypoxia.  Because the animals are allowed to survive after sample collection, the 
effect of NICU procedures on organ damage could be elucidated through multiple 
imaging modalities (magnetic resonance imaging and spectroscopy) or tissue assays. 
Data from these studies could be used to test efficacy of treatment strategies and to 
develop innovative nursing interventions to prevent and treat potentially adverse 
consequences of commonly performed NICU procedures in premature neonates [19, 20].  
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Abstract  
Preterm neonates exposed to painful NICU procedures exhibit increased pain 
scores and alterations in oxygenation and heart rate.  It is unclear whether these 
physiologic responses increase the risk of oxidative stress.  Using a prospective study 
design, we examined the relationship between a tissue-damaging procedure (TDP, tape 
removal during discontinuation of an indwelling central arterial or venous catheter) and 
oxidative stress in 80 preterm neonates.  Oxidative stress was quantified by measuring 
uric acid and malondialdehyde (MDA) concentration in plasma obtained before and after 
neonates experienced a TDP (n=38) compared to those not experiencing any TDP 
(control group, n=42).  Pain was measured before and during the TDP using the 
Premature Infant Pain Profile (PIPP).  We found that pain scores were higher in the TDP 
group compared to the control group (median scores: 11 and 5, respectively, P<0.001). 
Uric acid significantly decreased over time in control neonates but remained stable in 
TDP neonates (132.76M to 123.23M vs.140.50M to 138.9M, P=0.002).  MDA 
levels decreased over time in the control group but increased in the TDP group (2.07M 
to 1.81M vs. 2.07M to 2.21M, P=0.01).  We found a significant positive correlation 
between PIPP scores and MDA.  Our data suggest a significant relationship between 
procedural pain and oxidative stress in premature neonates.   
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Perspective 
This article presents data describing a significant relationship between 
physiological markers of neonatal pain and oxidative stress.  The method described in 
this paper can potentially be used to assess the direct cellular effects of procedural pain as 
well the effectiveness of interventions performed to decrease pain.   
 
Introduction 
During a typical stay in the neonatal intensive care unit (NICU), a newborn often 
experiences numerous painful procedures in the course of monitoring and treatment. 
Contrary to previously held convictions, premature neonates are able to perceive pain as 
demonstrated by several pain scoring methods [1, 2].  Such methods, however, tend to 
rely on a neonate’s alertness and ability to react expressively to the painful experiences.  
Consequently, caregivers are reluctant to treat pain if there appears to be no clear 
demonstration that it is occurring or if no immediate untoward effects are observed [3].  
An approach that allows the measurement of a systemic reaction to a painful stimulus has 
the potential benefit of providing objective means of evaluating the pain as well as the 
effectiveness of its treatment. 
It is well documented that exposure to painful procedures often results in 
tachycardia, which increases energy expenditure and oxygen consumption [4].  However, 
there are currently few data that quantify the effect of increase oxygen consumption on 
ATP metabolism.  Theoretically, an increase in oxygen consumption should increase the 
utilization and degradation of ATP to its purine byproducts, specifically uric acid (Figure 
1).  We made this observation in a pilot study from our laboratory in which we reported  
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Figure 1: Pathway from ATP to uric acid and lipid to MDA 
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increased uric acid concentration in rabbit kits subjected to a single heel lance [5].  
Because the process of purine degradation can result in the production of hydrogen 
peroxide, markers of oxidative stress can theoretically increase.  This was observed by 
Belliene et al. who showed increased markers of oxidative stress in the plasma of 
premature neonates experiencing a single heel lance [6].  However, no studies to date  
have examined the relationship between behavioral and physiological markers of pain 
and plasma markers of ATP utilization and oxidative stress.  Specifically, do markers of 
ATP utilization and oxidative stress increase as pain scores increase? 
To explore this question, we studied two groups of preterm neonates:  one group 
experiencing a common tissue damaging procedure (TDP group) and a second group not 
experiencing any TPD (control group).  The TDP was tape removal associated with the 
discontinuation of a central arterial or venous catheter.  Pain was measured before and 
during the TDP using the Premature Infant Pain Profile (PIPP), whose components 
include physiological (gestational age, heart rate, oxygen saturation) and behavioral 
(alertness and facial expressions) markers.  ATP degradation was quantified by 
measuring uric acid levels and oxidative stress was quantified by measuring 
malondialdehyde (MDA) in plasma obtained before and after the TDP.  Uric acid is a 
well-known end product of purine metabolism whose concentration is associated with 
increased ATP utilization, hypoxia, ischemia or increased ROS (Figure 1) [7].  
Malondialdehyde is a thiobarbituric acid–reacting substance that is formed by the action 
of ROS on lipid membranes (Figure 1) [8, 9].  Its use as a marker is relevant because the 
study of oxidative stress and pain in neonates is relatively recent and the association of 
pain with elevated MDA was reported in adults.  Elevated MDA concentrations were 
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observed in adult patients with vascular related pain [10], young women with 
dysmenorrheal pain [11, 12], adults with neuropathic pain [13] and adult  patients with 
acute abdominal pain [14].  More recently, MDA and 8-hydroxyguanosine were reported 
to significantly correlate with pain intensity in patients with temporomandibular joint 
disease [15]. 
Evaluation of the effects of pain in premature neonates is challenging.  We are 
presenting biochemical evidence that a single painful procedure is associated with a 
system wide perturbation in purine metabolism.  Furthermore, we show that a single TDP 
is also associated with elevated MDA levels (correlated with the PIPP score) suggesting 
distant effects in the form of oxidative damage to lipid membranes. 
 
Methods 
Subject Enrolment And Sampling Procedure 
We conducted a prospective cohort study at the Loma Linda University 
Children’s Hospital NICU.  The Loma Linda University Institutional Review Board 
approved study protocol and informed consent documents.  Families were approached for 
consent as soon as possible after birth.   
Preterm infants less than 37 weeks gestation that met the following inclusion 
criteria were considered for enrollment:  1) weight of more than 1000 grams at time of 
enrollment, 2) arterial or central venous catheter in place, 3) no signs or symptoms of 
hypoglycemia, hypovolemia, hypoperfusion, hyperbilirubinemia, clinical sepsis, pallor or 
moderate to severe respiratory distress, 4) absence of intraventricular hemorrhage grade 3 
or higher and 5) parental consent.  Exclusion criteria included 1) multiple congenital 
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abnormalities 2) facial malformation, 3) complex congenital heart disease 4) receiving 
analgesia or sedation and 5) endotracheal intubation. 
After parental consent was obtained, investigators collaborated with the clinical 
staff to obtain from a central catheter, approximately 0.8 ml of blood, before and 30 
minutes after the TDP to measure levels of uric acid and MDA.  In control neonates, 
similar samples were obtained at 0 and 30 minutes from baseline.  The time period of 30 
minutes after TDP for blood sample collection was based on previous investigations 
which showed plasma levels of MDA significantly increasing 15-30 minutes after 
ischemia-reperfusion [16, 17] and remaining elevated up to 2 hours later [18].  Our pilot 
study in rabbit kits also showed elevations of uric acid thirty minutes after a single heel 
lance [5].  To isolate the effects of TDP, subjects were given at least one hour of quiet 
time in which no TDPs were performed before baseline blood samples were drawn and 
no additional TDPs were performed during the study period.  Samples were centrifuged 
within five minutes to separate cells from plasma which was then stored at -80°C.  All 
stored plasma samples were analyzed within one week of acquisition. 
 
Pain Assessment 
To assess pain, we used the Premature Infant Pain Profile (PIPP), an instrument 
that was designed to assess acute pain in preterm neonates [19].  The scoring system 
includes seven items, each graded from 0 to 3.  Two items describe baseline 
characteristics of the neonate (gestational age and behavioral state), two items are derived 
from physiologic measurements (heart rate and oxygen saturation), and three items 
describe facial actions (brow bulge, eye squeeze, and nasolabial furrow).  Gestational age, 
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behavioral state, heart rate and oxygen saturation were assessed and recorded by a trained 
research nurse (LS) at the bedside.  Facial actions were assessed and scored by a 
neonatologist who was blinded to group assignment (KH), who had undergone training in 
the use of the PIPP and was experienced in observing and quantifying facial actions.  
Previous work on validation of the PIPP score showed an ability to differentiate painful 
from non-painful or baseline events (F = 48; P = .0001), with interrater reliability 
coefficients of 0.93 to 0.96 and intrarater reliability coefficients were 0.94 to 0.98 [19-21].  
 
Measurement Of MDA 
Plasma MDA levels were determined using an adaptation of the selected ion-
monitoring gas chromatography-mass spectrometry (GCMS; Agilent, Santa Clara, CA) 
analysis of phenylhydrazine-derivatized plasma, as described by Cighetti et al [22]. 
Specifically, the sample was prepared by the mixture of 0.1 ml plasma, 0.26 nmol methyl 
malondialdehyde (MMDA), 5 nmol butylated hydroxytoluene (10 µl of 0.5 mM) (Sigma, 
St. Louis, MO), 0.2 ml citrate buffer (0.4 M, pH 4.0), and deionized water, up to a final 
volume of 480 µl.  Then 20µl 50 mM phenylhydrazine (1 µmol) (Aldrich, St. Louis, MO) 
was added as the derivatizing agent.  After 30 min incubation at 25C, the samples were 
extracted with 1 ml hexane, vortexed for 1 min and centrifuged (3000 rpm, 10 min) at 
25C.  The organic phase was removed, concentrated by nitrogen stream to 100 µl, and 
analyzed by GCMS, in selected ion monitoring mode (injection volume of 2 µl).  Ion 
144.00 was monitored for MDA, and ion 158.00 for MMDA.  The ion abundance ratios 
were converted to micromolar concentrations by use of a standard curve.  All 
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measurements were performed in triplicate.  Values with coefficients of variation of less 
than 10% were included in the final analyses. 
The internal standard, MMDA, was synthesized using a modified method of 
Paroni et al [23].  Briefly, 2-methyl-3-ethoxyprop-2-enal (Sigma; St. Louis, MO) was 
suspended in 7 M NaOH and stirred for 150 min.  This was diluted with 5 ml of water 
and extracted with three 5 ml volumes of CH2Cl2.  After that, the water was evaporated 
from the aqueous layer.  The residue was crystallized once from 5 ml ethanol and 5 ml 
benzene and then three times from 5 ml ethanol and 5 ml diisopropyl ether.  The resulting 
white powder was diluted in water, filtered, and stored at -80°C. 
 
Measurement of Uric Acid 
Plasma was transferred to separate Eppendorf tubes, and immediately centrifuged 
within 5 minutes in Beckman Microfuge 22R (Fullerton, CA) for 30 minutes at 18000 x 
g, 4C.  The supernatant was immediately transferred to Microcon centrifugal filter 
devices (Millipore Corp.; Bedford, MA), 200 µl per device, and spun for 90 min at 14000 
x g, 4°C.  Filtrate was removed, and 150 µl was transferred to an Eppendorf tube 
containing 1 x 10-7 mol of 2-aminopurine (Sigma, St. Louis, MO) as the internal standard.  
Analysis was done the same day using high performance liquid chromatography (HPLC; 
Waters 996 PDA, 715 Ultra Wisp Sample Processor; Millipore Corp) or the tubes were 
frozen at -80°C until analysis could be performed.  Previous HPLC analysis demonstrated 
that uric acid values remained stable despite freezing. 
Three 45 µl injections were used for each sample.  Samples were injected onto a 
Supelcosil LC-18-S 15 cm x 4.6 mm, 5 µm column (Supelco, Sigma Aldrich, St. Louis, 
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MO), with the following isocratic conditions: 50 mM ammonium formate buffer, pH 5.5, 
flow rate 1.0 ml/min.  Uric acid concentration was quantitated by first obtaining 
integrated peak areas for uric acid and for 2-aminopurine at appropriate retention times 
and wavelengths, as described by our laboratory [24].  The peak area ratios of uric acid to 
2-aminopurine were determined and converted to micromolar concentrations using 
standard curves.  Samples were analyzed in triplicates and values with coefficients of 
variation of less than 10% were included in the final analyses.  The limit of detection for 
uric acid was 5.0 µM. 
 
Statistics 
At the time our study was planned, there were no studies that had examined the 
relationship between pain and oxidative stress in premature neonates.  We based our 
sample-size calculation on our pilot study that compared MDA and uric acid 
concentration in neonates born by elective cesarean section to those born by vaginal 
birth[24].  Based on that calculation, 35 subjects per group were required to demonstrate 
a difference between groups with 80% power and  = .05 (Sample Power 2.0, SPSS Inc, 
Chicago, IL).  We recruited additional subjects per group to account for data-collection 
errors.  The total sample size was 80 infants (Control n = 42 and TDP n = 38). 
Assumptions of normality and equal variance were assessed.  Demographic data 
for categorical variables were analyzed using Chi-square test.  Repeated measures 
ANOVA for one between subject factor (group) and one within subject factor (time) were 
assessed to evaluate the effect of the procedure (control vs. TDP) on plasma uric acid and 
MDA concentrations over time.  Interaction terms in the General Linear Model were used 
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for this purpose.  Percent change in uric acid, as well as MDA, between baseline and 
thirty-minute values were calculated as follows (Eq. 1):   
 
                            (([30min] – [0min]) / [0min]) x 100             Eq. 1 
 
Correlations between uric acid, MDA and biobehavioral markers (PIPP) were examined 
using Spearman’s rho.  All statistical analyses were performed using SPSS Statistics for 
Windows Version 17.  Differences were considered significant at P < 0.05. 
 
Results 
General Results 
Subject recruitment occurred from July 2007 to August 2009.  After obtaining parental 
consent, samples were obtained from 80 subjects that met study criteria.  As described in 
Table 1, no significant differences in demographics were demonstrated between the 
control and TDP group.  The clinical characteristics and the environmental condition of 
subjects at the time of sampling were also compared (Table 2).  At the time of sampling, 
no significant differences were observed in mode of ventilation, baseline oxygen 
saturation, postnatal age, fraction of inspired oxygen (FiO2), hemoglobin, acuity (as 
measured by SNAPPE-II), environmental noise, kidney function (as measured by BUN 
and creatinine) and number of exposure to TDPs  (Table 2).  
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Table 1.  Subject demographics. TDP: tissue damaging procedure; NS: not significant.  Data are 
Mean  SD. *Independent samples t-test,  +Chi-square 
 
 No Procedures Single TDP P Value* 
    
Number of Subjects 42 38  
Birth Weight (g) 1644 ± 486 1540 ± 389 NS 
Estimated Gestational 
Age (Weeks) 
31.2 ± 3 30.7 ± 3.3 NS 
Gender (%) Male 54.1 Male 54.1 NS+ 
Apgar-1 minute 6 ± 2 6 ± 3 NS 
Apgar-5 minute 8 ± 2 7 ± 3 NS 
Race (%) Caucasian   52.4 
Hispanic   23.8 
African American   14.3 
Asian   7.1 
Not Documented  2.4 
Caucasian   39.5 
Hispanic   44.7 
African American   10.5 
Asian   5.3 
Not Documented  0.0 
NS+ 
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Table 2. Physiological and Environmental Conditions at Time of Sampling. CPAP: 
continuous positive airway pressure, NIPPV: noninvasive positive pressure ventilation, NS: not 
significant. Data are mean±SD, * Independent samples t-test. 
 
 No Procedures Single TDP P Value* 
    
FiO2 0.24 ± 0.05 0.24 ± 0.07 NS 
Mode of Ventilation Room air = 24 (57.1%) 
Nasal cannula = 9 (21.4%) 
Nasal CPAP = 6 (14.3%) 
NIPPV = 3 (7.1%) 
Room air = 26 (68.4%) 
Nasal cannula = 4 (10.5%) 
Nasal CPAP = 5 (13.1%) 
NIPPV = 3 (7.9%) 
NS 
Baseline oxygen saturation (%) 97 ± 2.8 97 ± 3.6 NS 
Postnatal age (days) 20 ± 12 20 ± 15 NS 
Weight (g) 1850 ± 515 1890 ± 568 NS 
Hemoglobin (mg/dL) 12.7 ± 2.2 13.2 ± 2.2 NS 
SNAPPE-II score 7.9 ± 3.6 7.6 ± 5.5 NS 
Blood urea nitrogen (mg/dL) 16.8 ± 10.6 14.8 ± 8.3 NS 
Creatinine (mg/dL) 0.47 ± 0.19 0.46 ± 0.18 NS 
No. of TDPs from birth to time  
of sampling 
95 ± 69 107 ± 96 NS 
Environmental noise (dB) 51 ± 5 53 ± 4 NS 
 
 
 
Table 3. Pain Scores as Measured by PIPP. NS: not significant, * Mann-Whitney U test 
 
 No Procedure (N=42) TDP (N=38) P value * 
Baseline pain score (median) 3 (0-7) 3 (0-8) NS 
Procedural pain score (median) 5 (0-11) 11 (3-19) < 0.001 
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Procedural Pain Score As Measured By PIPP 
 As expected, neonates in the TDP group had significantly higher procedural pain 
scores compared to the control group (Table 3).  Median procedural pain scores were as 
follows: control group: 5 (min-max 0-11) and TDP group: 11 (min-max 3-19), P < 0.001 
(Table 3). 
 
Differences Between Baseline And Post-Procedure Uric Acid And 
MDA Levels In Control Vs. TDP Groups 
There were no significant differences in baseline uric acid and MDA levels 
between control and TDP groups.  However, although uric acid levels decreased over 
time in the control group, uric acid levels remained unchanged in the TDP group (Figure 
2).  More importantly, we saw a significant increase in MDA over time in the TDP group 
that was not observed in the control group (P = 0.02) (Figure 2).  
  
Correlation Between PIPP Pain Score And MDA 
 We found significant correlations between pain scores and MDA (Pearson 
correlation, 0.283, P = 0.012).  As the pain score increased, MDA levels also increased. 
In addition, we found significant correlations between procedural heart rate and MDA 
concentration (Correlation Coefficient 0.286, P = 0.014).  We observed that as heart rate 
increased, MDA concentration also increased.  More importantly, we also found a 
significant correlation between MDA concentration and oxygen saturation; as oxygen 
saturation decreased, MDA concentration increased (Correlation coefficient, 0.454, P 
<0.001).  We found no significant correlation between plasma uric acid levels and total 
PIPP pain scores. 
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Figure 2: Plasma [Uric Acid] and [MDA] at baseline and 30 minutes post-TDP. 
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Discussion 
Premature neonates in the intensive care unit have reduced endogenous substrate 
fuel stores and metabolic reserve [25].  Their ability to respond to acute stressors is 
limited due to their physiologic immaturity, which impedes their ability to mobilize 
substrate during catabolic metabolism [26].  Their response to routine NICU procedures 
often include significant alterations in transcutaneous oxygen levels (TcPO2) and heart 
rate [27, 28].  Because neonates have fixed stroke volumes, acute changes in heart rate 
can potentially reduce preload, decrease cardiac output and cause tissue hypoperfusion, 
increasing the risk of ischemia before compensatory mechanisms take effect.  Ischemia 
combined with decreased arterial oxygen tension can contribute to increased ATP 
utilization in the face of decreased ATP synthesis.  This can lead to enhanced degradation 
of ATP to adenosine diphosphate (ADP) and adenosine monophosphate (AMP) [29].  
Further degradation leads to dramatic increases in adenosine levels.  In turn, adenosine is 
converted to inosine and subsequently to hypoxanthine, xanthine, and uric acid (Figure 
1).  During conditions of decreased ATP supply, the enzyme xanthine oxidase is 
activated catalyzing the conversion of hypoxanthine to xanthine and xanthine to uric acid, 
while generating reactive oxygen species [30].  In this context, there has been little 
research evaluating the link between painful procedures, increased ATP utilization and 
oxidative stress in premature neonates.  
Our data demonstrate a significant relationship between procedural pain and 
MDA, a well-accepted marker of oxidative stress.  Specifically, we observed an increase 
in MDA in neonates exposed to a single painful procedure compared to those exposed to 
no such procedure.  None of the neonates in this study had conditions that were shown to 
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increase plasma MDA concentration such as moderate to severe respiratory distress, 
elevated FiO2 requirements, lipid infusions, hyperbilirubinemia [31, 32] or clinical signs 
of septicemia [33].  Instead, the elevated MDA is consistent with an increase in the 
production of reactive oxygen species secondary to enhanced ATP degradation (Figure 
1) in response to increased energy requirements and reduced oxygenation brought about 
by the painful procedure.  Elevations in heart rate and reductions in oxygen saturation 
significantly correlated to elevated MDA levels.  Further studies are required to 
investigate this mechanism as well as other possible mechanisms that may increase MDA 
such as pain-related tissue injury, inflammation and cytokine production.  To validate the 
relationship between procedural pain and oxidative stress, it will also be important to 
measure other oxidative stress markers, such as damage to DNA (8-hydroxy-2'-
deoxyguanosine), lipids (4-hydroxy-2-noneal, isoprostanes, isofurans) and nitration of 
proteins (nitroalbumin, nitrotyrosine, 3-nitro-4-hydroxyphenylacetic acid (NHPA) and 
para-hydroxyphenylacetic acid) in plasma and other biological fluids [34-36]. 
  Our findings have important implications for clinical practice.  Because neonates 
are exposed to multiple painful procedures per day [37, 38], previous investigations have 
focused on examining and decreasing the painful effects of these procedures.  A number 
of interventions, such as the use of sucrose [39-41], pacifiers [41, 42], or morphine [43, 
44] have been successful in decreasing signs of pain, but studies investigating the 
possible biochemical sequelae of painful procedures in neonates are needed.  If exposure 
to multiple painful procedures is shown to contribute to oxidative stress, biochemical 
markers of such stress might be useful to evaluate mechanism-based interventions that 
could decrease the adverse effects of exposure to these procedures. 
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 Although our findings are novel in the neonatal population, our study was 
performed without randomization.  The painful procedure (tape removal) was a clinical 
requirement necessary in the normal course of care in the NICU setting, and no additional 
painful procedures were employed solely for the benefit of a randomized experimental 
protocol.  However, as shown in Table 1, the demographic and clinical characteristics of 
subjects in both the control and TDP groups were not significantly different.  All of the 
subjects were clinically stable premature neonates, with minimal oxygen requirements 
and similar clinical acuity status.  Randomized trials that examine the biochemical effect 
of painful procedures in more acutely ill neonates with higher SNAPPE II scores are 
needed. 
 
Conclusion 
 Our data demonstrate an important relationship between exposure to a single 
painful procedure and oxidative stress.  Because neonates are exposed to many painful 
procedures during hospitalization, it is important to further examine the effect of single, 
multiple and accumulated TDPs in a randomized clinical trial.  Mechanistic studies that 
will determine whether or not procedure-related increases in oxidative stress exacerbate 
preexisting pathological conditions or trigger development of new abnormalities would 
provide insight.  
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Abstract 
Objective 
To examine the effects of sucrose on pain and biochemical markers of adenosine 
triphosphate (ATP) degradation and oxidative stress in preterm neonates experiencing a 
clinically required heel lance. 
  
Study Design 
Preterm neonates that met study criteria (n = 131) were randomized into 3 groups: 
(1) control; (2) heel lance treated with placebo and non-nutritive sucking; and (3) heel 
lance treated with sucrose and non-nutritive sucking.  Plasma markers of ATP 
degradation (hypoxanthine, xanthine, and uric acid) and oxidative stress (allantoin) were 
measured before and after the heel lance.  Pain was measured with the Premature Infant 
Pain Profile.  Data were analyzed by the use of repeated-measures ANOVA and 
Spearman rho. 
Results 
We found significant increases in plasma hypoxanthine and uric acid over time in 
neonates who received sucrose.  We also found a significant negative correlation between 
pain scores and plasma allantoin concentration in a subgroup of neonates who received 
sucrose. 
  
Conclusion 
A single dose of oral sucrose, given before heel lance, significantly increased 
ATP use and oxidative stress in premature neonates.  Because neonates are given 
multiple doses of sucrose per day, randomized trials are needed to examine the effects of 
repeated sucrose administration on ATP degradation, oxidative stress, and cell injury. 
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Background 
Premature neonates experience many painful procedures as part of their standard 
care in the neonatal intensive care unit [1, 2].  To prevent or treat procedural pain, the use 
of oral sucrose is recommended by many national and international clinical guidelines on 
the basis of results from multiple randomized clinical trials in which investigators 
determined sucrose to be effective in reducing signs of pain [3].  However, there are no 
studies to date in which investigators examine the effects of sucrose, a disaccharide of 
fructose and glucose, on neonatal cellular adenosine triphosphate (ATP) metabolism, 
despite the well-documented relationship between fructose metabolism and reductions in 
ATP synthesis in adult animals [4], in children ages 11 months to 12 years [5],  and in 
healthy adults [5, 6]. 
Inhibition of ATP synthesis, as a consequence of sucrose administration, may 
reduce a premature neonate's already modest ATP stores [7].  In addition, evidence shows 
that the administration of sucrose does not attenuate the tachycardia that often 
accompanies painful procedures [8].  In neonatal pigs and newborn lambs, tachycardia 
significantly increased glucose oxidation and myocardial oxygen requirement [9], which 
paralleled significant reductions in phosphocreatine/ATP and significant elevations in 
adenosine diphosphate (ADP) and inorganic phosphate [10].  More importantly, sucrose 
may not be an effective analgesic as evidenced by its lack of impact on neonatal 
nociceptive circuits in the brain and spinal cord [11].  Together, these considerations 
imply that oral sucrose administration may alter ATP metabolism and may have adverse 
cellular effects in neonates with limited energy stores. 
The aim of this study is to examine the effects of a single dose of oral sucrose on 
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behavioral/physiological markers of pain and biochemical markers of ATP metabolism 
and oxidative stress in premature neonates experiencing a clinically required heel lance.  
The heel lance was chosen because it is a frequent painful procedure in the neonatal 
intensive care unit, as shown in 26 different clinical trials [12].  Pain was quantified using 
the Premature Infant Pain Profile (PIPP) [13],  ATP metabolism was quantified by 
measuring plasma concentrations of purines (hypoxanthine, xanthine, and uric acid), 
which are well-documented markers of ATP use and breakdown, and oxidative stress, 
measured as plasma concentrations of allantoin, a well-accepted in vivo free radical 
marker [14]. 
 
Methods 
Subject Enrolment And Sampling Procedure 
We conducted a prospective double-blind randomized controlled study at Loma Linda 
University Children's Hospital neonatal intensive care unit.  Study protocol and informed 
consent documents were approved by the Loma Linda University Children's Hospital 
Institutional Review Board.  Subjects included in the study were premature infants ≤ 36.5 
weeks' gestation who: (1) weighed ≥800 g; (2) had a central catheter in place; and (3) 
required a heel lance.  Exclusion criteria included neonates: (1) with unstable 
oxygenation and hemodynamic status; (2) receiving opioids or sedatives or any 
antiepileptic medications; (3) diagnosed with intraventricular hemorrhage ≥ grade 3; or 
(4) with facial or multiple congenital anomalies that might alter the pain response.  The 
heel lance was performed for an accurate measurement of blood glucose from neonates 
receiving glucose-rich total parenteral nutrition through a central catheter.  Parents of 
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premature infants who met study criteria were approached for informed consent as soon 
after birth as possible.  With consent, subjects were randomized into 1 of 3 groups: (1) 
control; (2) placebo with non-nutritive sucking (NNS, or pacifier); or (3) sucrose (Sweet-
Ease; Children's Medical Ventures, Phillips Healthcare, Andover, Massachusetts) with 
NNS (Figure 1).  Randomization was performed by a research pharmacist, who used a 
permuted block randomization table generated by the study statistician.  The 
experimental procedure is described in Figure 2.  Investigators collaborated with the 
clinical staff to obtain a sample of approximately 0.8 mL of blood from a central catheter 
before (“0” minute) and 5 minutes after the heel lance to measure purine and allantoin 
levels.  In control neonates who did not receive a study drug or undergo a heel lance, 
similar samples were collected at “0” and 5 minutes from baseline.  The time period of 5 
minutes after heel lance for blood sample collection was based on previous 
investigations, which showed plasma levels of purines and organic hydroperoxides 
significantly increasing 5 minutes after conditions such as incomplete ischemia [15].  
These data were validated by unpublished preliminary studies in our laboratory, where 
we found increases in plasma purines compared with baseline five minutes after heel 
lance, and purine values that were less than baseline, 20-30 minutes after heel lance.  
Blood samples were centrifuged within 5 minutes to separate the plasma which was then 
stored at −80°C.  All samples were analyzed within 1 week of acquisition.  
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Figure 1.  Enrollment Flow Chart.  *Reasons why subjects were not sampled include: change 
in acuity or failure to meet study criteria after consent was obtained (n = 9); central line will not 
draw or lipids were being infused preventing sampling (n = 5); and line was discontinued before 
sampling could be scheduled (n = 6). 
 
 
 
  
Figure 2.  Study Procedure. *Control neonates received no study drug, no heel lance. PIPP and 
plasma markers are obtained at baseline and five minutes after baseline. 
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Heel Lance Procedure And Administration Of Study Drug 
The study drug was prepared immediately before the experimental procedure by 
the research pharmacist and labeled as “study drug” to ensure blinding.  The dose of 
sucrose was based on previously published studies in premature infants [12, 16-18].  
Neonates randomized to the sucrose group received a single dose of 24% sucrose in the 
following volumes: 2 mL for neonates >2 kg, 1.5 mL for neonates 1.5-2 kg, and 0.5 mL 
for neonates that were <1.5 kg.  The study drug was administered slowly via syringe to 
the anterior tongue along with a pacifier (NNS) 2 minutes before the heel lance.  Multiple 
studies showed that sucrose was most effective when given approximately two minutes 
before heel lance [8, 18-23].  Neonates randomized to the placebo group received an 
equal volume of sterile water to the anterior portion of the tongue along with a pacifier.  
The neonate's face was videotaped by trained research staff to record facial action at “0” 
minutes, during the heel lance and up to 30 seconds post heel lance. 
 
Pain Assessment 
To assess pain, we used the PIPP, an instrument designed to assess acute pain in 
preterm neonates [13].  This scoring system includes seven items, each graded from 0 to 
3.  Two items describe baseline characteristics of the neonate (gestational age and 
behavioral state), 2 items are derived from physiologic measurements (heart rate and 
oxygen saturation), and 3 items describe facial actions (brow bulge, eye squeeze, and 
nasolabial furrow).  Baseline pain was scored before the heel lance (0 minute) during a 
30-second window.  Procedural pain was scored from the time of heel lance to 30 
seconds after the lance.  Facial actions were recorded with a digital camera with real-time 
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counter that allowed for intensive slow motion stop frame, videocoding, and playback.  
Previous work on validation of the PIPP score showed an ability to differentiate painful 
from non-painful or baseline events [13, 24]. 
 
Measurement Of Purines 
Purine metabolites were measured as previously published by our laboratory [25].  
Specifically, plasma was removed, transferred to separate Eppendorf tubes, and 
immediately centrifuged in Eppendorf 5702R (Pittsburgh, Pennsylvania) centrifuge, for 
30 minutes at 18000 g.  The supernatant was transferred to Microcon centrifugal filter 
devices (Millipore Corp, Bedford, Massachusetts), 200 μL per device, and spun for 90 
minutes at 14000 g, 4°C.  Filtrate was removed, and 150 μL was transferred to an 
Eppendorf tube containing 1 × 10−7 mol of 2-aminopurine (internal standard).  High-
performance liquid chromatography (Waters 996 PDA, 715 Ultra Wisp Sample 
Processor; Millipore Corp) analysis was done in the same day, or the tubes were frozen at 
−80°C until analysis.  Previous analysis via high-performance liquid chromatography of 
plasma demonstrated that purines remained stable with freezing. 
Samples, 45-μL, were infected onto a Supelcosil LC-18-S 15 cm × 4.6 mm, 5-μm 
column (SGE, Austin, Texas), with the following isocratic conditions: 50 mM 
ammonium formate buffer, pH 5.5, flow rate 1.0 mL/min.  Hypoxanthine, xanthine, and 
uric acid were quantitated by obtaining peak areas at appropriate retention and 
wavelengths [26].  Once the peak area of 2-aminopurine at approximately 10.8 minutes 
and 305 nm was determined, the area ratios of hypoxanthine, xanthine, and uric acid to 2-
aminopurine were determined and converted to micromolar concentrations using standard 
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curves.  Samples were analyzed in triplicates and values with a coefficient of variation of 
less than 10% were included in the final analyses.  The limits of detection for the purines 
are as follows: 1.58 μM hypoxanthine, 1.32 μM xanthine, and 5.0 μM uric acid. 
 
Measurement of Allantoin 
Allantoin was measured in plasma using an adaptation of the method developed 
by Gruber et al [27] and Al-Khalaf and Reaveley [28].  Plasma (50 μL) was transferred to 
an Eppendorf tube containing 5 × 10−10 mol internal standard (50 μL 10 μM [15N]-labeled 
allantoin).  Spiked samples were simultaneously deproteinized and extracted by the 
addition of 100 μL of acetonitrile.  Samples were then vortexed and centrifuged at 20000 
g, 4°C for 5 minutes, and the supernatant was dried under N2.  After drying, 50 μL of 
MTBSTFA (N-methyl-N-tert-butyldimethylsilyltrifluoroacetamide) in pyridine (1:1 
vol/vol) was added and the derivatization reaction was facilitated by incubation at 50°C 
for 2 hours.   
Analysis was performed on Agilent 6890N Network GC System connected to an 
Agilent 5973 Inert Mass Selective Detector (both Agilent Technologies, Inc, Santa Clara, 
California).  Separation was performed using an Agilent 122-5532G capillary column 
(25.7 m length, 0.25 mm internal diameter).  Helium was used as the carrier gas at a flow 
rate of 1.5 mL/min.  Derivatized product (1 μL) was injected in split mode (split 20:1, 
split flow 29.4 mL/min, total flow 33.8 mL/min).  The initial column temperature was set 
at 100°C and held at that temperature for 2 minutes, then increased to 180°C at a rate of 
10°C/min.  The column was held at this temperature for 4 minutes and then increased to 
260°C at a rate of 20°C/min.  This temperature was maintained until the end of the run.  
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Allantoin was quantified using selected ion monitoring mode with the 398.00 m/z ion 
being monitored for allantoin and the 400.00 m/z for DL-allantoin-5-13C;1-15N.  The ion 
abundance ratios (398.00/400.00) were converted to micromolar concentrations by use of 
a standard curve. 
 
Statistical Analyses 
A repeated-measures ANOVA with one between factor (type of intervention) and 
one within factor (time) was used to compute the minimum sample size needed for this 
study.  The sample size was based on the following assumptions: (1) the significance 
level was set to 0.05; and (2) required power was 80%.  After adjusting for a 10% 
dropout rate, we enrolled 42-45 participants per group for a total of 131 subjects. 
To analyze the data, assumptions of normality and equal variance were assessed.  
Demographic data for categorical variables were analyzed by use of the χ2 test.  
Repeated-measures ANOVA for one between subject factor (group) and one within 
subject factor (time) were assessed to evaluate the effect of the heel lance on plasma 
purines and allantoin concentrations over time.  Interaction terms in the general linear 
model were used for this purpose.  The interaction terms assess the differences between 
the groups over time.  Correlations between purines, allantoin, and biobehavioral markers 
(PIPP) were examined with the Spearman rho.  All statistical analyses were performed 
using SPSS Statistics for Windows Version 20 (SPSS Inc, Chicago, Illinois).  Differences 
were considered significant at P < .05. 
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Results 
General Results 
Of the 151 subjects who provided consent between the months of July 2009 and 
February 2012, 131 subjects were randomized into 1 of 3 groups: control (n = 42), heel 
lance and placebo (n = 45), or heel lance and 24% sucrose (n = 44; Figure 1).  All 
subjects randomized to the heel lance groups were given a pacifier (NNS) immediately 
before, during, and after study drug administration.  There were no significant differences 
between the groups (Table I). 
 
Effects of Oral Sucrose on Behavioral and Physiological Markers of 
Pain 
There were no significant differences in baseline pain score between the 3 groups 
(Table II).  Sucrose significantly attenuated the increase in pain score in response to heel 
lance, compared with placebo (Table II).  The heart rate response to heel lance was 
greatest in the sucrose group (P < .001).  Heart rate increased by 11% in the sucrose 
group, compared with 6% in the placebo group and 0.5% in the control group.  We 
observed no significant changes in mean oxygen saturation in response to heel lance.  
These data suggest that the lower pain scores in the sucrose group were attributable to 
significant reductions in the behavioral components of the PIPP scoring tool and not from 
physiological markers of pain such as heart rate or oxygen saturation. 
 
Effects of Oral Sucrose on Markers of ATP Metabolism (Purines) and 
Oxidative Stress (Allantoin) 
There were no significant differences in baseline purine and allantoin levels in 
any of the groups.  However, although plasma purine and allantoin concentration 
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Table 1.  Subject demographics. EGA, estimated gestational age; NCPAP, nasal continuous 
positive airway pressure; NIPPV, noninvasive intermittent positive pressure ventilation; RA, 
room air; SNAPPE-II, Score for Neonatal Acute Physiology−Perinatal Extension-II. *One-way 
ANOVA.†  χ2 test. 
 
 Control 
(n = 42) 
Heel lance, 
placebo-NNS 
(n = 45) 
Heel lance, 
Sweet-Ease/NNS 
(n = 44) 
F value P value 
EGA, weeks 30.5 ± 2.6 30.3 ± 3.2 30.1 ± 3.1 0.218* .804 
Birth weight, g 1456.4 ± 502 1498.4 ± 706 1374.1 ± 552 0.499* .608 
Apgar, 1 minute 5 ± 3 5 ± 3 6 ± 2 0.961* .385 
Apgar, 5 minute 7 ± 2 7 ± 2 7 ± 2 1.008* .368 
Sex, n (%) 
 Male 
 Female 
25 (60%) 
17 (40%) 
22 (49%) 
23 (51%) 
22 (50%) 
22 (50%) 
 
1.175† 
 
.556 
 
Race, n (%) 
 White 
 Hispanic 
 African American 
 Asian 
 Other 
15 (36%) 
15 (36%) 
6 (14%) 
2 (4%) 
4 (10%) 
14 (31%) 
21 (47%) 
7 (16%) 
2 (4%) 
1 (2%) 
19 (43%) 
15 (34%) 
6 (14%) 
2 (4.5%) 
2 (4.5%) 
 
 
4.277† 
 
 
.831 
Condition at time of 
sampling 
     
 FiO2, % 0.25 ± 0.07 0.26 ± 0.09 0.23 ± 0.03 1.783* .172 
 EGA, weeks 32.5 ± 2.3 32.6 ± 2.6 33.1 ± 2.1 0.759* .470 
 SNAPPE-II 7.8 ± 10.8 7.9 ± 11.9 8.3 ± 11.6 0.020* .980 
 Mode of O2 delivery 
 Spontaneous RA 
 Nasal cannula 
 NCPAP 
 NIPPV 
19 
6 
6 
11 
 
19 
11 
6 
0 
 
24 
11 
1 
8 
 
 
6.861† 
 
.334 
 Hemoglobin 13.1 ± 2.4 12.7 ± 2.3 12.5 ± 2.2 0.846* .432 
 Hematocrit 38.7 ± 6.5 37.6 ± 6.4 36.9 ± 5.7 0.844* .433 
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Table 2.  Pain score, heart rate, and oxygen saturation *One-way ANOVA. † Sweet-Ease 
group significantly lower than control or placebo groups. ‡ Control group significantly lower than 
both heel lance groups. 
 
 
 
 
 
 
 
 
 
 Control (n = 42) Heel lance, 
placebo-NNS 
(n = 45) 
Heel lance, Sweet-
Ease/NNS (n = 44) 
F value P value 
Pain score Mean 
(min-max) 
 Baseline 
 
 Procedural 
3.9 (1-8) 3.8 (1-8) 3.8 (1-7) 0.233* .792 
5.9 (2-15) 6.3 (2-12) 4.6 (2-10) 6.216* .003† 
 
Heart rate 
 Baseline 
  
 Procedural 
154.4 (12.8) 155.9 (14.4) 154.1 (13.3) 0.206* .814 
154.9 (13.9) 164.9 (14.6) 170.5 (14.7) 14.480* <.001‡ 
 
Oxygen saturation 
 Baseline 
  
 Procedural 
96.5 (0.5) 96.2 (0.5) 96.2 (0.5) 0.123* .885 
96.2 (0.6) 95.8 (0.6) 96.4 (0.6) 0.235* .791 
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decreased over time in subjects randomized to the control and placebo groups, we 
observed a significant increase over time in plasma hypoxanthine and uric acid in 
neonates who received sucrose before the heel lance (Figure 3A and B).  This effect 
persisted even when analysis was limited to subjects <33 weeks' gestation at the time of 
sampling.  Xanthine concentrations remained stable over time in each of the 3 groups.  
Plasma allantoin concentration increased over time in those who received sucrose; 
however, this effect was not statistically significant (data not shown). 
 
Effects of Oral Sucrose on Plasma Allantoin in Neonates with a 
Minimal Pain Response to Heel Lance 
We found that 63% of neonates who received sucrose demonstrated a minimal 
response to heel lance, defined as an increase in PIPP score of <33%.  When we 
examined the effect of sucrose in this subgroup, we found that plasma allantoin 
concentration increased significantly over time (Figure 3C).  When we examined the 
correlation between the percent change in PIPP pain score over time and the percent 
change in allantoin concentration over time, we found a significant negative correlation 
(Spearman rho, −0.378, P = .014), suggesting that although sucrose significantly 
decreased the pain scores, it also increased markers of oxidative stress in this subgroup of 
premature neonates. 
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Figure 3.  Differences in Purine and Allantoin Concentrations 5 min post TDP. A and B, 
Plasma hypoxanthine and uric acid concentration increased over time in preterm neonates who 
received oral sucrose before a clinically required heel lance.  C, In neonates with minimal pain 
response (<33% increase in PIPP with heel lance), plasma allantoin concentration increased over 
time. 
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Discussion 
Although oral sucrose given before a single heel lance significantly decreased 
behavioral markers of pain, consistent with the findings of numerous clinical 
investigators [8, 17, 23, 29], it also increased markers of ATP use, as evidenced by 
significant increases over time in plasma hypoxanthine and uric acid concentrations.  The 
relationship between sucrose, ATP use/depletion, and increased purine production is well 
documented in adult animal and human literature (Figure 4)[6, 30, 31].  Sucrose is a 
disaccharide of glucose and fructose.  It is hydrolyzed by sucrase, an enzyme secreted by 
epithelial cells of the villi in the small intestine (Figure 4A).  Both glucose and fructose 
are rapidly absorbed from the gastrointestinal tract through glucose transporter GLUT5 
(fructose) and sodium-glucose cotransporter/GLUT2 (glucose) transporters in the apical 
membrane and transferred to the portal circulation via GLUT2 transporters in the 
basolateral membrane of enterocytes (Figure 4B).  The expression of these GLUTs is up-
regulated by exposure of intestinal lumen to fructose solutions [32] or by previous 
exposure to corticosteroids [33].  Once in circulation, glucose uptake is insulin-dependent 
while fructose uptake is independent of insulin [4].  Inside the cell, fructose is rapidly 
phosphorylated to form fructose-1-phosphate by the enzyme fructokinase (Figure 4C).  
The activity of fructokinase is 4-fold greater than glucokinase (the enzyme that 
phosphorylates glucose).  Moreover, fructokinase activity is relatively unregulated, 
being limited only by fructose concentration [34].  Fructose-1-phosphate is split by 
aldolase (aldolase B) into glyceraldehyde and dihydroxyacetone phosphate, a member of 
the glycolysis sequence of intermediates.  The third enzyme in the fructose pathway is 
triokinase, which catalyzes the phosphorylation of glyceraldehyde to glyceraldehyde-3- 
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Figure 4.  Sucrose metabolism.  A) Sucrose is hydrolyzed into fructose and glucose by the 
enzyme sucrase.  B) Glucose and fructose are absorbed from the gastrointestinal tract, transferred 
to the portal circulation, and enter hepatocytes.  C) Fructose is phosphorylated to form fructose-1-
phosphate by the enzyme fructokinase.  D) Fructose phosphorylation rapidly depletes the cell of 
ATP and inorganic phosphate.  E) Decreases in ATP production, in addition to increased ATP 
utilization, results in increased hypoxanthine, xanthine, and uric acid production.  If this is 
combined with increased oxidative stress, uric acid can be oxidized to form allantoin.  SGLT, 
sodium-glucose cotransporter; ISF, interstitial fluid; TCA, tricarboxylic acid cycle; IMP, inosine 
monophosphate. 
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phosphate, another intermediate in the glycolytic pathway. 
These fructose-related biochemical reactions are significant because each 
phosphorylation step requires ATP [31].  As ATP is consumed, it is degraded to ADP, 
leading to an increase in ADP concentration [4].  Simultaneously, inorganic phosphate 
levels decrease because they are sequestered in fructose-1-phosphate or the mitochondria 
to generate ATP necessary to maintain fructose phosphorylation (Figure 4D) [4].  As 
inorganic phosphate concentration decreases, oxidative phosphorylation is inhibited, 
reducing ATP synthesis and rapidly depleting ATP [4, 6, 30, 31].  ATP and ADP 
catabolism results in increased concentration of purines such as uric acid (Figure 4E) [5, 
6, 35].  These observations have been documented in adult animals as well as in children 
ages 11 months to 12 years [5] and in healthy adults [5, 6].  We show similar effects in 
preterm neonates, in which a single dose of sucrose significantly increased plasma 
hypoxanthine and uric acid concentrations. 
We also found that neonates in the sucrose treatment group had the largest 
increase in heart rate compared with those in the control or placebo groups, providing 
additional evidence that sucrose does not attenuate the tachycardia that accompanies 
painful procedures, but may increase it.  This increase in heart rate may be due to the 
stimulatory effect of sucrose on the sympathetic nervous system, as shown in rats [36, 37] 
and healthy young adults [38].  Interestingly, in humans, the sympathetic response to 
sucrose ingestion was enhanced under conditions of acute moderate hypoxia[39].  
Together, these data suggest that the apparent analgesic effect of oral sucrose may come 
at a price, namely tachycardia, which in turn contributes to increased ATP use. 
An additional finding of this study is the effect of sucrose administration on 
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plasma allantoin concentration in neonates with reduced pain responses (PIPP score 
increased by <33%).  We found that plasma allantoin increased over time when compared 
to control and placebo groups; however, this increase was only significant when neonates 
within the sucrose group who exhibited a larger pain response (defined as having an 
increase in PIPP score of ≥34% compared with baseline) were escluded (Figure 3C).  
The demographics of this subgroup of neonates were not significantly different from 
those with a larger pain response.  Although newborns with reduced pain responses had 
significantly lower baseline heart rates (151 ± 11.6 beats/min vs 159 ± 14.4 beats/min, 
P = .028), they tended to have a greater percent change in heart rate with the heel lance 
procedure compared with those with larger pain responses (12 ± 7% vs 9 ± 7%, P = .290).  
These data suggest that changes in heart rate due to sucrose administration may be more 
predictive of oxidative stress than changes in facial or behavioral activity.  Additional 
studies are required to examine the relationship between sucrose administration, pain 
reactivity, and oxidative stress. 
A limitation of this study is that although statistical power of more than 80% was 
achieved for hypoxanthine and uric acid, it was not achieved for allantoin.  A larger 
sample size may be required to adequately examine the effect of sucrose treatment on 
allantoin.  It is possible that a significant increase in allantoin may not be always evident 
five minutes after the heel lance procedure. 
In this prospective, randomized, double-blind study, we made the observation that 
a single dose of oral sucrose, given before a heel lance, significantly increased markers of 
ATP use and oxidative stress in premature neonates over time.  This finding suggests that 
the apparent analgesic effect of oral sucrose may come at a price, namely increased ATP 
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use.  Because neonates can be exposed to numerous painful procedures per day requiring 
multiple doses of sucrose, randomized trials should be performed to examine the effects 
of repeated sucrose administration not only on markers of ATP breakdown and oxidative 
stress but also on cellular injury.  If it is determined that the metabolic risks of using 
sucrose in neonates is indeed greater than the known benefits of reducing behavioral 
indices of pain, additional studies need to be performed to identify alternative effective 
substances or methods to prevent or treat pain in neonates. 
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Abstract  
Before urine can be used to evaluate the biochemical consequences of pain on 
adenosine triphosphate (ATP) utilization and oxidative stress, the clinical factors that 
alter the urinary concentrations of markers of ATP breakdown and oxidative stress need 
to be determined.  Here we report the effects of gestational age, weight for gestational 
age, and neonatal morbidity on urinary hypoxanthine, xanthine, uric acid, and allantoin.   
 Urine was collected from 294 premature infants born at <28weeks gestation 
(n=47), 28-306/7 weeks gestation (n=21), 31-33
6/7 weeks gestation (n=67), and 34-36
6/7 
weeks gestation (n=159).  Of the infants born between 34-366/7 weeks gestation, 22 
infants were small for gestational age (SGA), 125 infants were appropriate for gestational 
age (AGA), and 12 infants were large for gestational age (LGA).  The effect of neonatal 
morbidity was also determined in the 34-366/7 weeks gestation, late preterm, cohort.  The 
most prevalent morbidities within this group were poor nippling (n=11), poor nippling 
plus hyperbilirubinemia (n=24), poor nippling plus early respiratory disease (n=40), or 
respiratory disease alone (n=32).  HPLC and GCMS were used to evaluate the effects of 
gestational age, weight for gestational age, and mild morbidity on urinary markers of 
ATP utilization (hypoxanthine/creatinine, xanthine/creatinine, uric acid/creatinine) and 
oxidative stress (allantoin/creatinine).  
We found that infants born before 28 weeks estimated gestation age (EGA) had 
significantly higher mean day of life 1-4 urinary uric acid compared to infants born 
between 28-306/7 weeks EGA (P<0.001) as well as significantly higher urinary 
hypoxanthine, xanthine, uric acid and allantoin compared to infants born between 31-
336/7 weeks EGA (P<0.001 for all markers) and infants born between 34-36
6/7 weeks 
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gestation (P<0.001, P=0.002, P<0.001, and P<0.001 respectively).  In the late preterm 
cohort (34-366/7 weeks EGA) we found that SGA infants had significantly lower urinary 
hypoxanthine compared to AGA (P=0.020) and LGA (P=0.026) infants.  Also within this 
population, we found that respiratory morbidity significantly altered urinary purine 
concentrations.  Infants diagnosed with respiratory disease alone had significantly higher 
mean day of life 1-4 urinary hypoxanthine compared to infants diagnosed with poor 
nippling alone (P=0.003), poor nippling plus hyperbilirubinemia (P<0.001), or poor 
nippling plus early respiratory disease (P=0.003).  In addition, infants with respiratory 
disease had significantly higher xanthine compared to infants diagnosed with poor 
nippling plus hyperbilirubinemia (P=0.001) as well as significantly higher uric acid 
compared to infants with poor nippling alone (P=0.014).  Allantoin, a marker of oxidative 
stress, was only significantly altered by gestational age. 
These data indicate that factors such as gestational age, weight for gestational age 
and respiratory disease significantly alter markers of ATP breakdown and must be 
accounted for when using purines or allantoin to evaluate the biochemical consequences 
of pain.     
 
Background 
To examine the relationship between procedural pain and hypoxia in infants, our 
laboratory measured and reported alterations in plasma markers of adenosine triphosphate 
(ATP) utilization and oxidative stress in rabbit kits [1] and premature infants [2, 3] 
exposed to tape removal or heel lance, two painful procedures commonly performed in 
the neonatal intensive care unit (NICU).  These studies required subjects to have a central 
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arterial or venous catheter in order to obtain blood samples without causing additional 
pain; however, many infants in the NICU do not have a central line or have their lines 
discontinued soon after birth.  Furthermore, these studies were limited to evaluating a 
single painful procedure due to the limited blood volume of premature infants and to 
reduce the risk of infection.   
One possible solution to these problems is to utilize urinary biomarkers to identify 
the effects of procedural pain on oxidative stress and ATP utilization in premature 
infants.  Urine provides a non-invasive means of measuring purines and allantoin; 
however, these markers are not specific to pain.  Purine degradation products are well-
established markers of hypoxia [4-9].  When the supply of oxygen cannot meet tissue 
demand, metabolism switches from aerobic to anaerobic and ATP is broken down to 
generate energy [10].  The degradation of ATP results in elevated levels of adenosine 
monophosphate and free adenosine, which are subsequently catabolized into inosine 
monophosphate and inosine, respectively.  Both inosine monophosphate and inosine are 
then converted to hypoxanthine, then to xanthine, and finally to uric acid.  Uric acid has 
the ability to act as an antioxidant by scavenging reactive oxygen species which converts 
the compound mainly to allantoin, a marker of oxidative stress in humans [11].  Research 
indicates that allantoin is also elevated under conditions of ischemia-reperfusion and 
inflammation [12, 13].   
Because of the effects of tissue hypoxia on ATP metabolism, we examined 
common neonatal conditions that may cause measurable changes in the urinary 
concentrations of purines and allantoin.  Several investigators have reported that both 
gestational age and weight for gestational age affect neonatal mortality rates [14-16].  It 
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has further been reported that the that fractional excretion of uric acid is inversely related 
to gestational age [17].  Pulver et al. recently reported that even late preterm infants who 
are born small for gestational age are 44 times more likely to die in the first month of life 
and are 21 times more likely to die in the first year of life than appropriate weight for 
gestational age term infants [14].  To the best of our knowledge, the effects of weight for 
gestational age on purine and allantoin concentrations have not been reported in infants; 
however, research indicates that elevated maternal uric acid concentrations is associated 
with an increase rate of small for gestational age birth [18].    
It is also known that neonatal morbidities associated with poor prognosis or major 
neurological impairment (hypoxia-ischemia, asphyxia, intraventricular hemorrhage, and 
periventricular leukomalacia) increase ATP breakdown [8, 19, 20].  The effect of more 
mild morbidities (respiratory disease, hyperbilirubinemia, poor nippling) on oxidative 
stress and ATP breakdown has not been well studied.  Late preterm infants, infants born 
between 34 and 366/7 weeks gestation, provide a unique population for studying the 
effects of mild to moderate neonatal morbidity on ATP breakdown and oxidative stress.  
This population has a higher incidence of morbidity than term infants, but have lower 
incidence of morbidity than more premature infants [21-31].  The morbidities most 
frequently experienced by late preterm infants tend to be milder and include temperature 
instability, hypoglycemia, respiratory distress, hyperbilirubinemia, infection and feeding 
difficulties [22-31].  Many of these morbidities can be linked to increases in oxygen 
demand, metabolism, energy utilization, and oxidative stress (Figure 1).  In addition, 
these infants are less likely to have central lines than more premature infants and may 
benefit most from urinary analysis of purines and allantoin.  The goal of this study was to 
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determine the effect of gestational age, weight for gestational age, and mild/moderate 
neonatal morbidity on the urinary concentrations of purines and allantoin in premature 
infants.  Late preterm infants were chosen to evaluate the effects of mild/moderate 
morbidity for several reasons.  First, this population is less likely to have central lines 
when compared to more premature infants.  Second, research has already established the 
effects of severe morbidity on purine concentrations; however, the effects of clinically 
mild to moderate morbidities on the urinary concentrations of purines and allantoin is 
unknown.  Third, the late preterm population is understudied and often clinically 
managed as if they were term.  Lastly, because we hypothesized that urinary purine and 
allantoin excretions will be inversely related to gestational age, we wanted to control for 
gestation in our morbidity studies.  These studies reveal that gestational age, weight for 
gestational age, and morbidity alter the urinary excretion of purines and allantoin and 
need to be accounted for if these compounds are to be utilized to evaluate the metabolic 
consequences of pain in premature infants.   
The goal of this study was to determine the effect of gestational age, weight for 
gestational age, and mild/moderate neonatal morbidity on the urinary concentrations of 
purines and allantoin in premature infants.  Late preterm infants were chosen to evaluate 
the effects of mild/moderate morbidity for several reasons.  First, this population is less 
likely to have central lines when compared to more premature infants.  Second, research 
has already established the effects of severe morbidity on purine concentrations; 
however, the effects of clinically mild to moderate morbidities on the urinary 
concentrations of purines and allantoin is unknown.  Third, the late preterm population is 
understudied and often clinically managed as if they were term.  Lastly, because we  
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Figure 1. Pathway depicting the interrelationship between common late preterm morbidities and 
biochemical markers of ATP breakdown and oxidative stress. 
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hypothesized that urinary purine and allantoin excretions will be inversely related to 
gestational age, we wanted to control for gestation in our morbidity studies.  These 
studies reveal that gestational age, weight for gestational age, and morbidity alter the 
urinary excretion of purines and allantoin and need to be accounted for if these 
compounds are to be utilized to evaluate the metabolic consequences of pain in premature 
infants.   
 
Methods 
Subject Enrolment And Sample Collection 
Premature neonates admitted to Loma Linda University Children’s Hospital 
neonatal intensive care unit were included in this study.  The Loma Linda University 
Institutional Review Board approved study protocol and informed consent documents.  
No infants were excluded from the study; however, major anomalies, severe morbidity, 
and comorbidities were noted.  Weight for age and morbidity studies were carried out in 
late preterm infants.  Primary and secondary diagnosis was determined by a 
neonatologist.   
After parental consent was obtained, investigators collaborated with the clinical 
staff to obtain urine samples.  Urine was collected in 12-hour aliquots over the first seven 
days of life by placing cotton balls over the urethral meatus.  Urine-soaked cotton balls 
were removed with every diaper change and stored at 0oC.  Validation studies performed 
in our laboratory showed that purines, creatinine, and allantoin concentrations remained 
stable under our sampling and processing conditions.  Urine was extracted from the 
cotton using pressure, centrifuged for 10 min at 20000xg and 4oC, filtered through a 
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Millex syringe driven filter (Low Protein Binding Durapore PVD filter, 0.45um, 13mm; 
Millipore Corp.), and stored at -80oC until analysis.   
 
Subject Classification 
Infants with birth weights in the lower 10% or upper 90% of the weight for age 
growth chars were classified as small and large for gestational age respectively.  
Neonates with poor nippling are those with oral motor immaturity without signs and 
symptoms of feeding intolerance or necrotizing enterocolitis.  Neonates with poor 
nippling plus hyperbilirubinemia are those with oral motor immaturity who received 
phototherapy at some point over the first six days of life.  Neonates with poor nippling 
plus initial respiratory disease are those with oral motor immaturity and evidence of 
apnea or ventilatory support for three days or less.  Neonates with with respiratory 
disease alone are those with transient tachypnea of the newborn (TTNB) or radiographic 
evidence of respiratory distress syndrome (RDS) or pneumonia requiring oxygen and/or 
ventilatory support over at least a successive four-day period in the first six days of life.  
  
Purine And Creatinine Quantification 
Urinary purine and creatinine concentrations were determined using an adaptation 
of the HPLC method described by George et al [32].  Briefly, urine samples were thawed 
and sonicated before 200 µl was transferred to an Eppendorf tube containing 1 x 10-7 mol 
of 2-aminopurine (internal standard).  The samples were then analyzed on an HPLC 
(Waters 996 PDA, Waters 600 controller, and 717 plus autosampler; Millipore Corp) by 
injecting 35 µl onto a Supelcosil LC-18-S 15 cm x 4.6 mm, 5 µm column (SGE; Austin, 
TX), with the following isocratic conditions: 10 mM potassium dihydrogen phosphate 
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buffer, pH 4.7, flow rate 1.0 ml/min.  Creatinine, hypoxanthine, xanthine and uric acid 
were quantitated by obtaining peak areas at the appropriate retention times (~3.5, 8, 9.5, 
and 6.5 min respectively) and wavelengths (230, 248, 267, and 288nm respectively).  The 
area ratios of each compound to 2-aminopurine (13.5 min and 305 nm) were determined 
and converted into micromolar concentration using standard curves.  Samples were 
analyzed in triplicate and values with a coefficient of variation less than 10% were 
included in the final analysis.  The limits of detection for the purines and creatinine are as 
follows:  1.58 µM hypoxanthine, 1.32 µM xanthine, 5.0 µM uric acid, and 3.2 µM 
creatinine.     
 
Allantoin Quantification 
Urinary allantoin concentrations were determined using an adaptation of the gas 
chromatography mass spectrometry method described by Gruber et al[33].  Briefly, urine 
samples were thawed and sonicated before 25 µl was transferred to an Eppendorf tube 
containing 5x10-10 mol of internal standard (50µl of 10µM solution of 15N-labeled 
allantoin).  Spiked samples were deproteinated and extracted with 100 ml of acetonitrile. 
Samples were then vortexed, centrifuged at 4oC for 5 minutes at 20000 x g, and the 
supernatants were dried under N2.  After drying, 50 µl of MTBSTFA in pyridine (1:1 
vol/vol) was added and the derivatization reaction was facilitated by incubation at 50oC 
for 2 h.   
Analysis was performed on an Agilent 6890N Network GC System connected to 
an Agilent 5973 Inert Mass Selective Detector.  Separation was performed on an Agilent 
122-5532G capillary column (25.7m length, 0.25mm internal diameter) with helium, at a 
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flow rate of 1.5mL/min, as the carrier gas.  Allantoin was quantified using selected ion 
monitoring mode with the 398.00m/z ion being monitored for allantoin and the 
400.00m/z for DL-Allantoin-5-12C;1-15N.  The ion abundance ratios were converted to 
micromolar concentration units by use of a standard curve.  All measurements were 
performed in triplicate.  Values with a coefficient of variation of less than 10% were 
included in the final analyses.   
 
Stability Of Purines, Allantoin And Creatinine 
To determine the stability of hypoxanthine, xanthine, uric acid, allantoin, and 
creatinine over time and at varying temperatures, urine samples were collected from 
volunteers the compounds were measured by HPLC or GCMS.  Samples were subjected 
to the fallowing conditions: direct analysis, immediate cotton extraction and analysis, or 
incubation at room temperature (3 hours, 24 hours, 3 days, and 1 week), 36oC (3 hours or 
6 hours), 0oC (24 hours or 1 week), or -80oC (24 hours or 1 week).  Purines and 
creatinine as well as the ratio of each to creatinine were found to be stable under all 
conditions tested with coefficient of variation between the mean concentrations for each 
processing condition being within 10% of fresh urine.  Allantoin, on the other hand, 
significantly increased in concentration when left at room temperature for 24 hours but 
remained stable when incubated at 36oC for 6 hours or stored at temperatures of 0oC and 
lower.   
 
Statistics 
 To analyze the data, assumptions of normality and equal variance were assessed. 
Demographic data for categorical variables were analyzed using Chi-square test.  One-
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way ANOVA was used to evaluate the effects of gestational age, weight for gestational 
age, and morbidity on mean DOL 1-4 urinary purines and allantoin.  All statistical 
analyses were performed using SPSS Statistics for Mac OS Version 21.  Differences were 
considered significant at P < 0.05. 
 
Results 
General Results  
Urine was collected from 294 premature infants born at <28weeks gestation 
(n=47), 28-306/7 weeks gestation (n=21), 31-33
6/7 weeks gestation (n=67), and 34-36
6/7 
weeks gestation (n=159).  As expected, significant differences were observed between 
gestational age groups for 1-min Apgar, 5-min Apgar, and birth weight (Table 1).  There 
was also a trend for more males in each group except for the poor nippling plus 
hyperbilirubinemia group.  Of the infants born between 34-366/7 weeks gestation, 22 
infants were SGA, 125 infants were AGA, and 12 infants were LGA.  No significant 
differences were found between these groups; however, LGA infants tended to have 
lower Apgar scores and a large majority were born via cesarean section (Table 2).   
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Table 1: Subject Demographics for Gestational Age Groups.  SVD: Spontaneous vaginal 
delivery; C/S: Cesarean Section; Data are Mean ± SD; *One-way ANOVA, †Chi-square test 
‡<28 and 28-306/7 significantly different from 31-336/7 and 34-366/7. <28 and 28-306/7 
significantly different from all other groups. All groups are significantly different from one 
another. 
 
 
 
 
 
 
 
 
<28 
(n=47) 
28-306/7 
(n=21) 
31-336/7 
(n=67) 
34-366/7 
(n=159) 
P value* 
Apgar, 1 min 4 ± 3 5 ± 2 7 ± 2 7 ± 2 0.000‡ 
Apgar, 5 min 6 ± 2 7 ± 2 8 ± 1 8 ± 2 0.000 
 
Birth Weight (g) 
829.5 ± 
187.4 
1150.6 ± 
275.5 
1875.4 ± 
308.1 
2325.0 ± 
493.3 
 
0.000 
Gender, n  (%) 
Male 32 
(68.1%) 
6 
(8.6%) 
37 
(55.2%) 
83 
(52.2%) 
 
0.024† 
Female 15 
(31.9%) 
15 
(71.4%) 
30 
(44.8%) 
76 
(47.8%) 
Mode of Birth, n  (%) 
SVD 
 
C/S 
15 
(31.9%) 
5 
(23.8%) 
22 
(32.8%) 
63 
(39.6%) 
 
NS 
(0.409)† 
32 
(68.1%) 
16 
(76.2%) 
45 
(67.2%) 
96 
(60.4%) 
Weight for age, n  (%) 
 
AGA 
 
SGA 
 
LGA 
44 
(93.6%) 
16 
(76.2%) 
58 
(86.6%) 
125 
(78.6%) 
 
NS  
(0.153)† 
1 
(2.1%) 
3 
(14.3%) 
8 
(11.9%) 
22 
(13.8%) 
2 
(4.3%) 
2 
(9.5%) 
1 
(1.5%) 
13 
(7.5%) 
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Table 2: Subject Demographics for Weight for Gestational Age Groups. EGA: estimated 
gestational age; SVD: Spontaneous vaginal delivery; C/S: Cesarean Section; Data are Mean ± 
SD; *One-way ANOVA, †Chi-square test 
 
 SGA 
(n=22) 
AGA 
(n=125) 
LGA 
 (n=12) 
P value* 
Apgar, 1 min 7 ± 2 7 ± 2 5 ± 3 NS  (0.141) 
APGAR, 5 min 8 ± 1 8 ± 1 7 ± 2 NS (0.058) 
EGA (weeks) 
35 ± 0.8 35 ± 0.8 35 ± 0.8 
NS (0.325) 
Gender, n  (%) 
Male 
 
Female 
 
12 
(54.5%) 
65 
(52.0%) 
6 
(50.0%) 
 
NS (0.964)† 
10 
(45.5%) 
60 
(48.0%) 
6 
(50.0%) 
 
Mode of Birth, n  (%) 
 
SVD 
 
C/S 
 
 
8 
(36.4%) 
54 
(43.2%) 
1 
(8.3%) 
 
 
NS (0.059)† 
14 
(63.6%) 
71 
(56.8%) 
11 
(91.7%) 
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Table 3: Subject Demographics for Late Preterm Morbidity Groups. EGA: estimated 
gestational age; SVD: Spontaneous vaginal delivery; C/S: Cesarean Section; Data are Mean ± 
SD; *One-way ANOVA; †Chi-square test. ‡All groups significantly different than Respiratory 
Disease. Poor nippling plus Hyperbilirubinemia significantly different from Poor nippling plus 
Mild Respiratory Disease and Respiratory Disease alone.  +Respiratory disease significantly 
different from Poor nippling plus Hyperbilirubinemia and Poor nippling plus Mild Respiratory 
Disease 
 
 
 
 Poor 
Nippling 
(n=11) 
Poor Nippling plus 
Hyperbilirubinemia 
(n=24) 
Poor Nippling plus 
Early Respiratory 
Disease 
(n=40) 
Respiratory 
Disease 
 (n=32) 
P value* 
Apgar, 1 min 7 ± 2 7 ± 2 7 ± 2 6 ± 3 NS (0.393) 
 
Apgar, 5 min 9 ± 1 9 ± 21 8 ± 1 7 ± 2 0.000‡ 
 
EGA (weeks) 35 ± 0.7 34 ± 0.4 35 ± 0.7 35 ± 0.7 0.001 
 
Birth Weight 
(g) 
2251.7 ± 
721.8 
2108.8 ± 
455.2 
2294.5 ± 
387.9 
2593.1 ± 
463.1 
 
0.002+ 
 
 
Gender, n  (%) 
Male 
 
Female 
 
 
 
8 
(72.7%) 
14 
(58.3%) 
20 
(50.0%) 
15 
(46.9%) 
 
 
 
NS 
(0.454)† 
3 
(27.3%) 
10 
(41.7%) 
20 
(50.0%) 
17 
(53.1%) 
 
Mode of Birth, 
n  (%) 
SVD 
 
C/S 
 
 
 
5 
(45.5%) 
17 
(70.8%) 
18 
(46.2%) 
9 
(28.1%) 
 
 
 
0.018† 
6 
(54.5%) 
7 
(29.2%) 
21 
(53.8%) 
23 
(71.9%) 
 
 
Weight for 
age, n  (%) 
AGA 
 
 
SGA 
 
LGA 
 
 
 
 
8 
(72.7%) 
19 
(79.2%) 
33 
(82.5%) 
24 
(75.0%) 
 
 
 
 
NS 
(0.107)† 
2 
(18.2%) 
4 
(16.7%) 
6 
(15.0%) 
2 
(6.3%) 
1 
(9.1%) 
1 
(4.2%) 
1 
(2.5%) 
6 
(18.8%) 
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The effect of neonatal morbidity was determined in the late preterm, 34-366/7 weeks 
gestation, cohort.  The most prevalent morbidities within this group were poor nippling 
(n=11), poor nippling plus hyperbilirubinemia (n=24), poor nippling plus early 
respiratory disease (n-40), or respiratory disease alone (n=32).  Significant differences 
were observed between morbidity groups for 5-min Apgar (P<0.001), gestational age 
(P=0.001), and birth weigh (P=0.002, Table 3).  We also noted that more infants in the 
poor nippling plus hyperbilirubinemia group were born via spontaneous vaginal 
deliveries versus cesarean section. 
 
Effect Of Gestational Age On Purine Catabolites And Allantoin 
There was a trend for infants of lower gestation to have higher purines and 
allantoin (Figure 2).  Specifically, infants born at < 28 weeks gestation had significantly 
higher mean day of life 1-4 urinary uric acid (P<0.001) and allantoin (P=0.043) compared 
to infants born between 28-306/7 weeks gestation.  Similarly, infants born at <28 weeks 
gestation also had significantly higher hypoxanthine, xanthine, uric acid and allantoin 
compared to infants born between 31-336/7 weeks gestation (P<0.001 for all markers) and 
infants born between 34-366/7 weeks gestation (P<0.001, P=0.002, P<0.001, and P<0.001 
respectively).  In addition, infants born between 28-306/7 weeks gestation had 
significantly higher hypoxanthine, uric acid, and allantoin compared to infants born 
between 31-336/7 weeks gestation (P=0.030, P=0.001, P<0.001 respectively) and infants 
born between 34-366/7 weeks gestation (P=0.033, P<0.001, and P<0.001 respectively). 
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Figure 2. Effect of gestational age on mean day of life 1-4 urinary purines and allantoin. A) 
hypoxanthine/creatinine, B) xanthine/creatinine, C) uric acid/creatinine, and D) 
allantoin/creatinine.  Bars are mean ± standard error of the mean. *Significantly different from 
<28 weeks, †Significantly different from <28 and 28-306/7.   
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Effect Of Weight For Gestational Age On Urinary Excretion Of Purines And Allantoin 
 After controlling for gestational age by selecting for infants between 34-366/7 
weeks gestation we found that SGA infants had significantly lower hypoxanthine 
compared to AGA (P=0.020) and LGA (P=0.037) infants (Figure 3A).  No significant 
differences were found between weight for gestational groups for xanthine, uric acid, or 
allantoin (Figure 3B-D).  
 
Effect Of Morbidity On Purines And Allantoin In Late Preterm Infants 
 Infants diagnosed as having respiratory disease alone had significantly higher 
hypoxanthine than infants diagnosed with poor nippling alone (P=0.003), poor nippling 
plus hyperbilirubinemia (P<0.001), or poor nippling plus early respiratory disease 
(P=0.003, Figure 4A).  Xanthine was found to be significantly lower in infants diagnosed 
with poor nippling plus hyperbilirubinemia (P=0.001) compared to infants diagnosed 
with respiratory disease alone (Figure 4B).  Infants diagnosed with poor nippling alone 
had significantly lower uric acid (P=0.014) compared to infants diagnosed with 
respiratory disease alone (Figure 4C).  Urinary allantoin was not significantly different 
between any of the groups (Figure 4D).  
 
Discussion 
The aim of this study was to examine the effects of gestational age, weight for gestational 
age, and mild morbidity on the urinary concentration of purines and allantoin.  We found 
that gestational age significantly altered the urinary concentrations of purines and 
allantoin.  Weight for gestational age also altered the urinary concentration of purines and 
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allantoin; however, the changes were only significant for hypoxanthine.  In addition, 
neonatal morbidity significantly changed urinary purines in that infants diagnosed with 
respiratory disease alone had the highest concentration for all purines.   
Previous studies have demonstrated an inverse relationship between gestational age and 
uric acid [17].  Our data provide additional support for higher urinary purine 
concentration in infants at the lowest gestational age groups, until roughly 31 weeks 
gestation.  In addition, we also report significantly higher allantoin, a marker of 
inflammation and oxidative stress, in more premature infants.  The observed increase in 
urinary purine and allantoin concentrations could be caused by increased purine and 
allantoin production and/or increased renal clearance.  It is known that infants excrete 
substantially greater quantities of uric acid per unit of body weight than adults or older 
children [17, 34, 35].  Stapleton et al. reported that fractional excretion of uric acid was 
nearly 70% for infants born between 29-31 weeks gestation and decreased to roughly 
40% for infants born between 38-40 weeks gestation [17].  Increased urinary purine 
concentrations were also shown to be a result of clinical conditions associated with 
hypoxia or perinatal asphyxia [19, 36, 37].  Our data provide additional support that uric 
acid is easily filtered and excreted and can be altered by prematurity and conditions that 
increase ATP utilization.  The mechanism for urinary excretion of allantoin is not well 
studied; however, it was demonstrated that elevated urinary allantoin concentration were 
associated with increased oxidative stress in adults exposed to continuous exercise or 
therapies that increase synthesis of free radicals [38, 39], establishing this compound as 
an important free radical marker in urine.  
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Figure 3. Effect of weight for age on mean day of life 1-4 urinary purines and allantoin. A) 
hypoxanthine/creatinine, B) xanthine/creatinine, C) uric acid/creatinine, and D) 
allantoin/creatinine.  SGA: small for gestational age, AGA: appropriate for gestational age, LGA: 
large for gestational age.  Bars are mean ± standard error of the mean. *Significantly different 
from SGA. 
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Figure 4. Effect of morbidity on urinary purines and allantoin in late preterm infants.  A) 
hypoxanthine/creatinine, B) xanthine/creatinine, C) uric acid/creatinine, and D) 
allantoin/creatinine. PN: poor nippling; PNHB: poor nippling plus hyperbilirubinemia; PNRD: 
poor nippling plus early respiratory disease; RD: respiratory disease.  Bars are mean ± standard 
error of the mean. *Significantly different from respiratory disease. 
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To the best of our knowledge, we are the first to report the effects of weight for 
gestational age on urinary purine and allantoin concentrations in late preterm infants.   
Surprisingly, we found that SGA infants tended to have lower urinary purine 
concentrations than AGA or LGA infants; with SGA infants having significantly lower 
hypoxanthine than both AGA and LGA infants.  This trend continued, but was not 
significant, after controlling for neonatal co-morbidities (data not shown).  The 
mechanism for this reduction in urinary purines in SGA infants is unclear but could be a 
result of increased purine salvage, decreased energy use/purine production, or decreased 
renal clearance. However, an increase in purine salvage is unlikely because 
hypoxanthine-guanine phosphoribosyltransferase (HGPRT) activity was shown to be 
depressed in cord blood lymphocyte from SGA infants when compared to term infants 
[40].  Furthermore, this is not likely a result of an overall reduction in purine metabolism 
because this same study found similar adenosine deaminase activity between premature 
SGA infants and term infants.  This study, however, compared preterm SGA infants to 
term infants.  The HGPRT activity for SGA infants needs to be compared to age matched 
AGA infants for purine salvage to be ruled out as an explanation for the decreased 
urinary purine concentrations observed in our study.  
It was further reported that SGA infants have similar metabolic parameters and 
higher resting energy expenditure than age matched AGA infants in the first week of life; 
indicating that the observed decrease in urinary purines in SGA infants may be due to 
decreased excretion rather than decreased production [41].  Wang et al. reported higher 
insulin levels in SGA infants compared to age matched AGA infants at 72 hours of 
life[42].  Research indicates that hyperinsulinemia decreases uric acid excretion without 
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significantly altering plasma uric acid concentration in adults [43].  Bauer et al., however, 
have reported similar blood insulin levels between SGA and AGA infants [41].  Studies 
investigating the mechanism of decreased urinary purine excretion in SGA infants need 
to be conducted.  Based upon these studies, as well as the data presented in the paper, it is 
important to control for, or exclude, SGA infants from studies that use urinary purines as 
markers of ATP breakdown.   
We also found that respiratory morbidity within the late preterm population can 
significantly alter urinary purines, but not allantoin.  This was most evident for urinary 
hypoxanthine.  The elevated urinary purine concentrations in infant with respiratory 
disease could be caused by decreased ATP production or increased ATP utilization.  It is 
well documented that hypoxia and asphyxia resulted in increased purine levels [5-9, 44].  
In addition, it has been reported that plasma uric acid positively correlated with fraction 
of inspired oxygen (FiO2) in intubated premature infants [45].  In this study, FiO2 was 
adjusted per patient need.  In our study, all of the infants in the respiratory morbidity 
group were receiving oxygen and/or ventilatory support, indicating a need for 
supplemental oxygen or assisted breathing and an increased purine production.  It has 
also been reported that respiratory morbidity can increase energy expenditure in 
premature infants [46, 47].  The increase in purines observed in our study could be a 
result of increased ATP utilization due to increased energy expenditure.  It is well 
documented that increases in energy expenditure result in increased purine production 
[48, 49].  Our data indicate that infants with respiratory morbidities need to be grouped 
separately from infants without respiratory morbidities if urinary purines are to be used to 
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measure the relationship between procedural pain and hypoxia on ATP breakdown in 
urine.   
These data suggest that gestational age, weight for gestational age, and neonatal 
morbidity alter the urinary concentration of purine metabolites.  Allantoin was also found 
to be significantly altered by gestational age.  Based upon these data, we recommend 
conducting age-matched as well as weight for age-matched studies when using urinary 
purines and allantoin to evaluate the relationship between procedural pain and hypoxia on 
ATP utilization and oxidative stress. Lastly, it is important to stratify subjects based on 
health status or morbidity, due to the significant effects of neonatal respiratory diseases 
on ATP use and oxidative stress. 
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